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ABSTRACT 
The soil bacterium Streptomyces peucetius produces two widely used anticancer 
antibiotics doxorubicin and daunorubicin.  Present within the biosynthesis gene cluster in S. 
peucetius is the drrAB operon which codes for a dedicated ATP-binding cassette type transporter 
for the export of these two closely related antibiotics.  DrrAB system was believed to be the 
single-drug transporter due to its dedicated nature; however, our study demonstrated under both 
in vivo and in vitro conditions that DrrAB system can transport not only doxorubicin but also 
Hoechst 33342 and ethidium bromide.  Moreover, many other well-studied multi-drug resistance 
proteins substrates (including verapamil, vinblastine and rifampicin) inhibit DrrAB-mediated 
doxorubicin transport, indicating they are also substrates of DrrAB pump. Kinetic studies show 
competitive inhibition of doxorubicin transport by Hoechst 33342 and rifampicin and non-
competitive inhibition by verapamil, suggesting the possibility of more than one drug binding 
site in the DrrAB system.  This is the first in-depth study of a drug resistance system from a 
producer organism, and it shows that a dedicated efflux system like DrrAB contains specificity 
for multiple drugs.   
Our study also provides the first direct evidence for the dual role of the metalloprotease 
FtsH in the biogenesis of membrane proteins. We found that FtsH is not only responsible for 
proteolysis of unassembled DrrB protein but it also plays a much broader role in biogenesis of 
the DrrAB complex.  DrrA and DrrB proteins expressed together in a temperature sensitive ftsH 
mutant strain were found to be non-functional due to their incorrect assembly.  Simultaneous 
expression of wild-type FtsH in trans resulted in normal doxorubicin efflux.  Strikingly, 
doxorubicin efflux could be restored in mutant cells irrespective of whether FtsH was expressed 
simultaneously with DrrAB or expressed after these proteins had already accumulated in an 
inactive conformation, thus providing crucial evidence for the ability of FtsH to refold the 
misassembled proteins.  Complementation experiments also showed that the catalytic ATP 
binding domain of FtsH contains a chaperone-like activity, however both the catalytic and the 
proteolytic domains of FtsH are required to be present and work coordinately to participate in 
biogenesis of DrrAB complex in the membrane.  
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1 GENERAL INTRODUCTION 
1.1 Multidrug Resistance and ABC Transporters 
In the chemotherapies of cancer and infectious diseases, multidrug resistance (MDR) is 
seen to develop in more than 90% of the patients.  This resistance can be caused by the decreased 
uptake of drugs, altered cell cycle checkpoint, altered drug target or the increased efflux of drugs 
by drug transporter (1).  In tumor cells, the major reason for multidrug resistance is the over 
efflux of anti-cancer drugs. The first and the most well-characterized multidrug transporter in 
human cells is P-glycoprotein (P-gp), which belongs to the ATP-binding cassette (ABC) 
superfamily.  Proteins in this family share highly conserved domains and functions, including 
nucleotide binding domains (NBDs) and transmembrane domains (TMDs).  Members of the 
ABC superfamily range from prokaryotes to eukaryotes.   In eukaryotes, most ABC transporters 
only carry out drug efflux, while in prokaryotes, ABC proteins include both importers and 
exporters (2).    
Most members of the ABC superfamily mediate the transport of highly specific 
substrates, following the “lock-key” hypothesis (3); however, some transporters and are 
categorized as multidrug transporters.  Well-characterized multidrug transporters in eukaryotic or 
prokaryotic cells include P-gp, MsbA, LmrA and Sav1866, etc. (4-7).  This study focuses on the 
prototype drug transporter DrrAB found in Streptomyces peucetius, a soil organism that produces 
anticancer drugs doxorubicin (Dox) and daunorubicin (Dnr) (8).  The DrrAB system shows 
sequence, structural and functional similarities to the P-gp drug transporter of human cells (9,10).   
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1.2 Characterization of P-glycoprotein  
P-gp is known as multidrug resistance protein 1 (MDR1) or ATP-binding cassette sub-
family B member 1 (ABCB1).  It was first discovered by Biedler and coworkers, who found that 
Chinese Hamster cells, which are resistant to actinomycin D, are also cross-resistant to other 
several antibiotics (11).  
 P-gp is encoded by a single polypeptide chain with 1280 amino acids and assembled as 
two homologous halves in the plasma membrane (12).  These two halves are not identical, but 
share 43% sequence identity and 78% similarity (12).  They are connected by a central linker.  
Each half contains one TMD (with six transmembrane helices (TMH)) and one cytoplasmic ATP 
binding domain or NBD (13).  The two TMDs from each halve form a large drug transport 
channel with 12 TMHs connected by loops, while the two ATP binding domains constitute the 
cytosolic ATP binding pockets.  The NBD contains conserved motifs shared by other proteins in 
the ABC transporter family, such as Walker A (P-loop), Walker B, ABC signature, Q-loop and 
switch region (H-loop) (14).  These conserved motifs are involved in ATP binding and 
hydrolysis, energy transduction, and the cross-talk between NBD and TMD.  The NBDs of most 
ABC transporters share high homology irrespective of their substrate specificities while the 
sequence and structure of TMDs varies significantly (15).   
P-gp is expressed in tumor cells and normal tissue cells, its main physiological function is 
to protect sensitive organs, such as intestine, brain or placenta by pumping the drugs or toxic 
agents into bile, urine or lumen of gastrointestinal tract (16).  In tumor cells, P-gp is over-
expressed thus leading to the resistance of anti-cancer drugs used for chemotherapy.  
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1.3 P-glycoprotein is a multidrug transporter 
P-gp can interact with a wide range of structurally unrelated chemical compounds, 
including natural products, anticancer drugs, steroids, fluorescent dyes, linear and cyclic 
peptides, etc.  According to the type of interactions, these drugs are classified as substrates or 
modulators. Substrates that are transported by P-gp through the membrane, such as 
anthracyclines (doxorubicin, daunomycin), and vinca alkaloids (vincristine, vinblastine) (17).  P-
gp can also translocate fluorescent phospholipids such as C6-NBD-diacylglycerol (18) or lipid-
based drugs.  Modulators can block the function of the transporter and generate a drug 
concentration gradient; some of them can also be effluxed by the transporter, such as verapamil 
and cyclosporine A (19).  A modulator has very significant clinical application by reversing the 
multidrug resistance problem during cancer chemotherapy.  A combination of anti-cancer drugs 
and modulators will greatly improve the effect of cancer cells treatment (20).   
1.4 Mechanism of drug transport 
Gottesman and co-workers had proposed the hydrophobic vacuum cleaner model (4,17), 
which now has been extended to many other MDR proteins (21).    In this model, substrate first 
interacts with the lipids phase.  With the energy provided by ATP hydrolysis, P-gp detects the 
hydrophobic substrate from the lipid bilayer and extracts the substrates from inner leaflet to the 
extracellular medium (22-26).  Strong evidences to support this hypothesis include the early 
studies by Victor Ling’s group, which suggested that P-glycoprotein transports Hoechst 33342 or 
LDS-751 from the cytoplasmic leaflet of the plasma membrane directly to the extracellular 
medium (22,27,28).  LmrA, the homologue of Pgp, may also transport lipophilic substrate by a 
vacuum cleaner mechanism (29).   
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  The complete process of drug efflux requires a series of conformational changes of the 
drug transporter, which can be divided into four steps (30,31). 
(1) Initial binding of substrate to the drug binding pocket; 
(2) ATP binding and dimerization of two NBDs;  
(3) Hydrolysis of ATP resulting in the efflux of the drugs, which causes drug binding affinity 
to switch from high to low; 
(4) Resetting of the transport back to the original state after the reaction cycle. 
1.5 Drug binding sites on Pgp 
During the last two decades, the studies of P-gp drug transporter have revealed specific 
drug binding locations, the kinetic interactions of multiple drugs and the energy coupling 
between ATP hydrolysis and drug efflux.  
As P-gp can interact with unrelated chemical compounds, the question whether Pgp 
contains one single flexible and open drug binding site or multiple drug binding sites with 
different binding affinities is still not clear.  The presence of multiple drug interaction sites has 
been demonstrated by a number of groups.  For example, in 1997, Shapiro and Ling’s group 
identified two drug binding sites on P-gp.  The H-site preferentially transports Hoechst 33342 
and the R-site preferentially transports rhodamine 123 (32).  These two sites interact in a 
cooperative manner.  Later, they further discovered the third drug-binding site, which has a 
positively allosteric effect on the drug transport through H and R sites (33).  In 2000, Richard 
Callaghan found the presence of at least four distinct drug interaction sties on P-gp using 
equilibrium and kinetic radioligand binding assays (34).  Specific residues potentially involved 
in the drug binding were subsequently identified by Loo and Clark via a combination of cysteine 
scanning mutagenesis and thiol-modification techniques.  The thiol-reactive compounds include 
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the drug substrate dibromobimane (dBBn) (35-37) and the drug substrate analogues 
methanethiosulfonate (MTS)-verapamil (38) or MTS rhodamine (39).   First, single cysteine 
substitution mutation of every residue in the TMDs was generated; the expression level and 
function of these mutations were confirmed.  The residues protected by drug substrates from 
being labeled by thiol-reactive analogs were identified as potential drug binding sites.  This work 
showed that residues in TMHs 4-6 in TMD1and TMHs 9-12 in TMD2 of P-gp are involved in 
the drug binding process. 
P-gp has been proven to contain multiple drug binding sites by various techniques; 
however, other studies suggest that P-gp contains a large single drug binding pocket .  Loo and 
Clark showed that the P-gp drug binding pocket can bind verapamil and TMEA simultaneously, 
and these two drugs may occupy different regions of the shared drug-binding pocket (40).  This 
phenotype is also supported by low-resolution cryo-election microscopy structure of P-gp, which 
present the existence of a large, 5 nm diameter, central chamber for drug binding inside of P-gp 
(41).  A much clearer crystal structure was not obtained until 2009 by Chang’s group.  The apo-
P-gp structure contains an internal cavity of ~6,000 Å
3
 with a 30 Å separation of two NBDs (42).  
This large internal cavity could fit at least two substrates simultaneously and the drug binding 
pocket is mainly occupied by hydrophobic and aromatic residues (43-46).   
1.6 DrrAB is a multidrug transporter 
Streptomyces peucetius produces two anti-cancer drugs, Dox and Dnr, and is self-
resistant to these drugs due to the efflux action of membrane transporter DrrAB (47).  DrrA and 
DrrB proteins are coded by the drrAB operon  present within the Dox biosynthesis gene cluster 
(47).  DrrA is the catalytic subunit (36 kDa).  It belongs to the ABC family of proteins and binds 
ATP in a Dox-dependent manner (48).  DrrB is an integral membrane protein (30 kDa) with 
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eight transmembrane α-helices and belongs to the ABC-2 subfamily (3).   Two subunits each of 
DrrA and DrrB interact together to form a functional tetrameric complex (49).  Both DrrAB and 
P-gp belong to the ABC (ATP-binding cassette) superfamily of proteins.  The DrrAB system 
belongs to the Class III, DRA family, and DRR subfamily of ABC proteins (50).  The NBD of 
DrrA shares 29% identity and 47% similarity to NBD1 and NBD2 of Pgp (48).  Thus the 
bacterial DrrAB system could serve as a prototype model system for understanding the function 
and evolution of multidrug transporters in general.   
Due to it dedicated nature, the DrrAB system was previously believed to form a single-
drug-transporter.  However, in our recent studies, it was shown that DrrAB is a multidrug 
transporter that can carry out efflux of at least 3 different drugs: Dox, Hoechst 33342 and 
ethidium bromide (8).  Inhibition studies also suggest that DrrAB can interact with a number of 
other well-characterized MDR substrates, such as verapamil, rifampicin and colchicine.  The 
interactions between two different drugs in DrrAB were also studied by kinetics analysis, which 
revealed competitive inhibition of Dox efflux by Hoechst 33342 and rifampicin but non-
competitive inhibition of Dox efflux by verapamil.  These findings indicate that DrrAB is a 
multidrug transporter with at least two drug binding sites.  This work also highlights overlaps of 
the substrate specificity of the DrrAB system and Pgp as well as other bacterial MDR systems 
and points to a common mechanism, and perhaps origin, for most MDR proteins. 
1.7 Quality control of MDR proteins in membranes 
One of the major causes of MDR is the over-expression of the drug transporters, which 
results in efflux of anti-cancer drugs out of the cancer cells.  Our previous studies have indicated 
that DrrA and DrrB proteins need to co-assemble in the membrane to maintain the normal 
function of the DrrAB complex (51).  In the absence of DrrA, the expression of DrrB is 
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undetectable due to its proteolysis by FtsH on the membrane.  FtsH, also defined as HflB, is an 
inner membrane-embedded, ATP and Zn
2+
-dependent metalloprotease (52).  It has been shown 
to play a role in quality control of soluble proteins, such as σ32, as well as membrane proteins 
including SecY and YccA, etc. (53-55).  FtsH protein consists of two domains: the N-terminal 
AAA domain which carries out hydrolysis of ATP, and the C-terminal proteolytic domain (52).  
The degradation process of FtsH is triggered by the hydrolysis of ATP and conformational 
changes of the hexameric ring structure of FtsH (52).  Once the peptide tail is bound by FtsH, the 
peptide can be unfolded to an open structure, extracted from the membrane lipid bilayer and 
translocated through the central pore into the protease chamber for further digestion (56).  As 
FtsH has relatively low unfolding activity, it preferentially degrades proteins with natural 
structure or low thermostabilities (57).   
In our studies, we have demonstrated that FtsH plays dual roles in the quality control of 
the DrrAB complex; it is not only involved in proteolysis of the unassembled DrrB protein, but 
also facilitates assembly of the DrrAB complex (58).  We showed that the DrrAB complex is 
improperly assembled in an FtsH-deficient 
 
cell and loses its drug efflux function.  However, 
when FtsH is co-expressed in trans in FtsH-deficient cells, the function of the DrrAB complex is 
fully restored.  Interestingly, the Dox efflux activity could be restored in FtsH-deficient cells 
irrespective of whether FtsH was expressed simultaneously with DrrAB or expressed after these 
proteins had already accumulated in a misfolded conformation.  To facilitate this assembly 
function, both the AAA domain and proteolytic domain need to be present and work 
coordinately to refold the misfolded DrrAB into correct conformation.  
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2 DUAL ROLE OF THE METALLOPROTEASE FTSH IN BIOGENESIS OF THE 
DRRAB DRUG TRANSPORTER 
2.1 Introduction 
Membrane proteins play essential roles in cell physiology.  They carry out import of 
nutrients, export of toxins, antibiotics and drugs, and play important roles in energy and signal 
transduction.   Improper assembly of membrane proteins is known to result in various diseases.  
However, because of the complexity of the assembly process and the diverse array of factors 
involved, understanding mechanisms of membrane protein assembly poses a serious challenge.  
The bacterial DrrAB (doxorubicin resistance proteins A and B) system is an attractive model for 
studying assembly of ABC (ATP-Binding Cassette) transporters.  In this system, the catalytic 
function (DrrA) and the transport function (DrrB) are present on separate subunits (59), which 
together form a tetrameric complex in the membrane (60) and carry out ATP-dependent efflux of 
the anti-cancer drugs doxorubicin (Dox) and daunorubicin (61).  Previous studies from this lab 
suggested that for proper function of the DrrAB complex the DrrA and DrrB proteins may be 
required to co-assemble (51).  It was also shown that interaction between DrrA and DrrB is 
essential for stable maintenance of DrrB in the membrane so that the expression of DrrB is 
undetectable in the absence of a simultaneous expression of DrrA (60).  Co-expression of DrrA 
in cis or trans restores the wild-type levels of DrrB expression, therefore suggesting that DrrA 
protects DrrB from proteolysis by a cellular protease.  The nature of the protease and whether it 
plays a specific role in quality control and biogenesis of the DrrAB complex has so far remained 
uncharacterized.  In this study, we examine the role of FtsH (filament temperature-sensitive 
protein H) in this process.   
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FtsH is a zinc-dependent metalloprotease which belongs to the AAA (ATPases 
Associated with Diverse Cellular Activities) family of proteins.  Along with other proteases, 
such as ClpAP, ClpXP, HsIUV, and Lon, these proteins form the large AAA
+
 superfamily of 
proteins, members of which share a similar AAA-ATPase domain (62).  FtsH is evolutionarily 
conserved with more than 40% sequence identity observed between bacterial, yeast and human 
homologs (63).  E. coli FtsH is the best studied of all known members, and it has been shown to 
be the only growth-essential protease in E. coli.  Yeast cells lacking the three FtsH orthologs 
(two m-AAA and one i-AAA) were also found to be non-viable, demonstrating the essential 
function of this enzyme in eukaryotic cells (63,64).  FtsH is unique in being embedded in the cell 
membrane in E. coli, and in the mitochondrial inner membrane in eukaryotes (65), where it 
forms homohexameric ring-like structures.  The major role of FtsH is believed to be in the 
quality control of specific membrane proteins, such as degradation of the unassembled SecY and 
subunit ‘a’ of F0 sector of the ATP synthase, in addition to modulating levels of some soluble 
regulatory proteins (65-67). 
FtsH contains two transmembrane helices at the N terminus, followed by a cytoplasmic 
domain containing the catalytic AAA domain in the middle and the proteolytic domain at the C 
terminus.  The AAA domain (residues 144-398) consists of the conserved Walker A, Walker B 
and SRH (second region of homology) motifs, which are essential for ATP binding and 
hydrolysis (65).  The proteolytic domain contains the conserved Zn
2+
 binding motif 
H
417
EXXH
421
, the third Zn
2+
-ligand residue E
479
, and the coiled-coil leucine-zipper sequence 
(65).  FtsH carries out proteolysis of polypeptides in an ATP and Zn
2+
-dependent manner, while 
other AAA+ proteases, such as Lon and ClpA/P, are serine peptidases (68).  To initiate 
proteolysis of a membrane protein, the putative polypeptide binding site in the catalytic AAA 
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domain of FtsH is believed to capture the cytoplasmic tail (either at the N or the C terminus) of 
the membrane substrate, followed by dislocation and processive unfolding of the protein to an 
open structure (65).  Therefore, both the catalytic AAA domain and the proteolytic domain are 
required for proteolysis. 
Although the major function of the AAA
+
 proteases is in proteolysis, they also exhibit 
chaperone-like activities, which allow them to monitor the folding status of a protein, promote 
disassembly or unfolding (69), and specifically degrade non-native proteins (70).  For a long 
time, it has been speculated that the AAA
+
 proteases may also have the ability to refold their 
substrate proteins (71), which remains an open question till date (72).  FtsH was originally 
identified by Ito and co-workers in a screen to isolate factors which may assist in membrane 
protein assembly (73).  They used SecY-PhoA fusion to screen for stop-transfer defect (Std) 
mutations, and found that such a mutation lies in the ftsH gene.  Depletion of FtsH also resulted 
in significant export defects of β-lactamase and OmpA in E. coli in addition to causing a strong 
Std phenotype.  Together, these studies indicated that FtsH may be involved in protein assembly 
into and through the membrane and may play a role in determining orientation of membrane 
proteins (73).  In another study, FtsH orthologs Yta10 and Yta12 in yeast mitochondria were 
shown to be required for the formation of a 48 kDa assembly intermediate of the F0 subunit 9 
(74).  Finally, in vitro studies showed that the purified AAA domain of Yme1, a yeast 
mitochondrial homolog of FtsH, suppresses aggregation of a model polypeptide (75).  Despite 
these observations, however, no direct evidence for the role of FtsH or its homologs in functional 
assembly of membrane proteins has been obtained so far.  
In this study, we provide the first direct evidence that FtsH is a dual function enzyme 
containing both the protease and assembly functions.  We show that not only is FtsH responsible 
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for removal of the unassembled DrrB but that it is actually able to refold previously 
misassembled DrrAB proteins and restore Dox efflux function of the complex.  Our results also 
show that while the AAA domain of FtsH provides recognition and specificity for binding of the 
substrate, both ATP hydrolysis and the proteolytic functions of FtsH are used concurrently for 
refolding of DrrAB and restoration of function.  Our studies, therefore, not only shed light on the 
mechanism of assembly of the DrrAB complex but also further elucidate the function of the FtsH 
protease.   
2.2 Materials and Methods 
Strains and plasmids – The E. coli strains and plasmids are described in Table 1.  
Media and growth conditions – E. coli cells were normally grown in LB medium at 30°C or 37 
°C, unless indicated otherwise.  Chloramphenicol, kanamycin, or ampicillin was added to a final 
concentration of 20, 30 or 100 µg/ml, respectively, where indicated.  E. coli cells used for the 
Dox efflux assay were grown in TEA medium (61). 
Site-directed mutagenesis of ftsH – Site-directed mutagenesis of the ftsH gene was carried out 
by a Strategene QuickChange Multisite-directed mutagenesis kit (La Jolla, CA).  Using 
pUC18/ftsH plasmid as the template, Lys
198
, located in the conserved Walker A motif of the 
AAA domain, was changed to aspargine.  The resulting plasmid was named pUCftsH(K198N).  
Another mutant, named ftsH(HEH), was obtained by substituting His
417
Glu
418
His
421 
in the 
conserved HEAGH motif present in the proteolytic domain to Ala
417
Gln
418
Ala
421
.  The primers 
for both substitutions are shown in Table S1. 
Subcloning of the AAA domain of ftsH into pUC18 vector – To completely remove the 
proteolytic domain, a fragment of ftsH corresponding to the first 1194 base pairs was PCR-
amplified and ligated into the pUC18 vector using the EcoRI and HindIII restriction enzymes 
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resulting in pUC18(AAA).  This construct is referred to as ftsH(AAA) in this article. The primers 
are shown in Table S1.  
Subcloning of ftsH and the groESL genes – Wild-type ftsH, ftsH(K198N),  ftsH(HEH) and 
ftsH(AAA) genes were subcloned into pET28a vector using SnaBI and HindIII restriction 
enzymes.  The resulting plasmids were named pETftsH, pETftsH(K198N), pETftsH(HEH) and 
pETftsH(AAA), respectively.  The groES/L genes were subcloned from pKY326 (76) into 
pUC18 vector using EcoRI and SmaI restriction enzymes resulting in pUCgroESL 
Cloning of ftsH into the pBAD vector – Using pBAD/HisA (Invitrogen) as a template, a 3.9kb 
fragment between NcoI and HindIII sites was amplified.  The NcoI site was substituted with the 
XhoI site in the primers used for amplification (Table S1).  This resulted in deletion of the 
multiple cloning sites and the polyhistidine region.  The ftsH gene was amplifed from pUCftsH 
using primers containing XhoI and HindIII sites and ligated to the above fragment.  
Growth and Protein expression – E. coli TG1, AR796, AR797, E. coli SG1110, and E. coli 
SG1126 cells containing the indicated plasmids were grown at 30 °C or 37 °C to mid-log phase 
(A600nm=0.6).  The proteins were induced by addition of 0.1 or 0.25 mM IPTG, and the 
incubation was continued at 30 °C, 37 °C, or 42 °C for 3 h.  The cells were spun down, 
resuspended in 5 ml lysis buffer (2 mM Tris-Cl, pH 7.5, 20% glycerol, 2mM EDTA, 1 mM 
DTT) and lysed by a single passage through a French pressure cell at 20,000 p.s.i.  After 
centrifugation at 10,000 X g for 15 min, the pellet represented the inclusion body fraction.  The 
supernatant was centrifuged at 100,000 X g for 1 h to separate the supernatant (cytosolic 
fraction) and the pellet (membrane fraction).  The membrane, cytosol and the inclusion body 
fractions were analyzed by 12% SDS-PAGE, followed by Western-blot analysis using anti-DrrA 
or anti-DrrB antibodies (60).   
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Purification of the FtsH protein – FtsH protein was purified according to published protocols 
(66) with modifications.  E. coli HMS174(DE3) cells containing the pETftsH plasmid or its 
variants were inoculated in 1liter LB medium supplemented with 30 µg/ml kanamycin at 37 °C.  
The cells were grown to mid-log phase and induced with 0.25 mM IPTG at 20 °C overnight.  
The membrane fraction was prepared as described earlier (60).  5 mg of the membrane fraction 
was solubilized with 5 ml solubilization buffer (50 mM Tris-Cl, pH7.5, 500 mM KCl, 0.5 % 
(w/v) Nonidet P-40, 15% (w/v) Glycerol, 2.9 mM 2-mercaptoethanol).  The solubilized protein 
was purified using Ni
2+
 -NTA-agarose column and eluted with a gradient of 50 to 500 mM 
imidazole.  Fractions containing FtsH were collected and dialyzed against 2 liters of the dialysis 
buffer (10 mM Tris-Cl, pH7.5, 15% (w/v) glycerol, 50 mM KCl, 0.5% (w/v) Nonidet P-40, 5mM 
MgCl2, 1 mM dithiothreitol) for 12 hours.  The protein was stored at -80 °C until used.   
ATPase activity assay – The ATPase activity of FtsH was detected by the malachite green-
ammonium molybdate colorimetric assay (66).   
In vivo FtsH Proteolytic assay - Membrane-bound DrrAB proteins were used as a substrate to 
determine the proteolytic activity of FtsH.  pBAD vector or the pBADftsH plasmid was 
transformed into AR797 cells containing pDX101 (pSU2718drrAB).  The cells were grown in 
LB medium to mid-log phase and the DrrAB proteins were induced with 0.25 mM IPTG at 42 
°C for 1 h.  To terminate the synthesis of DrrAB, 1000 µg/ml chloramphenicol was added to the 
cell culture and incubated at 42 °C for 30 min.  The cells were washed extensively to remove 
chloramphenicol and IPTG.  After resuspending the cells in fresh medium, synthesis of FtsH 
from the pBADftsH plasmid was induced by addition of 0.2% arabinose at 42 °C.  An aliquot of 
cell culture was taken out at 0, 30, 60, 90, 120 and 180 min.  Membrane fractions were prepared 
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as described above, and 20 µg total membrane protein was loaded onto 12% SDS-PAGE, 
followed by Western-blot analysis using anti-DrrA, anti-DrrB or anti-FtsH antibodies.  
In vitro FtsH Proteolytic assay - α-Casein was used as a substrate in vitro to demonstrate the 
proteolytic activity of purified FtsH and the FtsH(HEH) protein (77).  40 µg of α-casein (Sigma 
Aldrich) was mixed with 40 µg purified FtsH or FtsH (HEH) in 150 µl protease buffer (50 mM 
Tris-Cl, pH8.0, 20 mM KCl, 5 mM MgCl2, 12.5 µM Zn(OAc)2, 0.5 % (w/v) NP-40, 10 % (w/v) 
glycerol, 1 mM dithiothreitol) at 42 °C.  The reaction was initiated by adding 8 mM ATP, and an 
aliquot (20 µl) of the sample was taken out at the indicated time points.  The reaction was 
terminated by adding 7 µl of 4×SDS sample buffer.  The samples were analyzed by 12% SDS-
PAGE, followed by Coomassie Brilliant blue staining.  
Whole cell Dox efflux assay – The whole cell Dox efflux assay was carried out according to the 
protocol published previously (61).  The fluorescence spectra were recorded on an Alphascan-2 
spectrofluorometer (Photon Technology International, London, Ontario, Canada).  The slope of 
the Dox efflux curve of the positive control (the first sample) in each panel was designated as 
1.0.  The efficiency of Dox efflux of each sample within one panel was calculated by dividing 
the slope of the efflux curve by the slope of sample 1.  The average data obtained from three 
independent experiments were plotted in the histograms. 
2.3 Results 
FtsH is responsible for the proteolysis of unassembled DrrB – Previous studies from this 
laboratory showed that DrrB is undetectable in wild-type E. coli membranes in the absence of 
simultaneous expression of DrrA ((60), Fig 1A, lane 2), however stable expression of DrrB is 
seen when both DrrA and DrrB are expressed together (lane 1).  These results suggest that DrrB 
is completely degraded when not complexed with DrrA.  Review of recent literature suggested 
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that proteins of the AAA
+
 family, especially FtsH, may be involved in the quality control of 
membrane proteins (70).  To determine if this is true for DrrB, three proteases, including Lon, 
ClpA/ClpP and FtsH, were investigated.  If any of these proteases is responsible for degradation 
of unassembled DrrB, stable expression of DrrB will be observed in cells deficient in that 
protease as compared to the wild-type cells.  The FtsH-deficient E. coli AR797 strain (Table 1) 
used in this study contains a temperature sensitive mutation in the ftsH gene, therefore it was 
grown at 30 °C but the temperature was switched to 42 °C to inactivate FtsH.  The Lon
-
 
(SG1110) and the ClpA
-
 (SG1126) cells were grown normally at 30 °C or 37 °C.  The isogenic 
E. coli AR796 parent strain was used as a control.  Of the 3 protease-deficient strains tested, only 
the FtsH-deficient E. coli cells showed stable expression of DrrB in the absence of DrrA (Fig. 
1B, lanes 1-3) (Fig. 1C, lane 2), while the Lon
-
 and the ClpA
-
 cells showed no effect on the 
stability of DrrB (Fig. 1C, lanes 3-4).  Since DrrB was not seen in AR796 (wild-type) cells at 
either 30 °C or 42 °C (Fig. 1B, lanes 1 and 2), but it was stably expressed in the 797 (FtsH
ts
) 
cells at 42 °C (lane 3), these results show that FtsH degrades unassembled DrrB.  In contrast to 
the expression of DrrB alone, when both DrrA and DrrB were expressed together in wild-type 
796 cells at 30 °C or 42 °C, stable expression of DrrB was seen (Fig. 1B, lanes 4 and 5), 
confirming that DrrA protects DrrB against FtsH proteolysis.  Note that the amount of DrrA and 
DrrB in the wild-type  cells was less at 42 °C as compared to at 30 °C (Fig. 1B, lanes 4-5), 
suggesting that the DrrAB complex acquires a more open conformation at higher temperature 
resulting in partial proteolysis by endogenous FtsH.  Protection of DrrB from FtsH proteolysis by 
DrrA was also seen in the ClpA
-
 and Lon
-
 backgrounds (Fig. 1C, lanes 5-6).  Together, the data 
in Fig. 1 show that FtsH plays an important role in quality control of the DrrB protein when 
DrrA is absent.  To rule out the possibility that DrrA or DrrB may aggregate when their 
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expression is induced at 42 °C, the membrane, cytosol, and inclusion body fractions were 
prepared from both wild type and FtsH
ts
 cells and analyzed by Western blotting using anti-DrrA 
and anti-DrrB antibodies.  The data in Fig. 2 show that although some DrrB protein is present in 
the inclusion body fraction in both wild type (lower panel, lane 3) and the FtsH
ts
 cells (lane 9) at 
30 °C, the induction of either strain at 42 °C did not result in any increase in the amount of 
inclusion body formation (lower panel, lanes 6 and 12).  Moreover, no aggregated DrrAB 
proteins were seen in the stacking region of the gel in any of the fractions of wild type or FtsH
ts 
cells, indicating absence of any significant aggregation under the conditions used in these 
experiments.  Note that the anti-DrrB antibody is an anti-peptide antibody, therefore it shows 
some cross-reactivity with epitopes in some other E. coli proteins, as explained in a previous 
publication (1).  
Expression of DrrB alone or DrrAB together in FtsH-deficient cells results in growth 
inhibition-  The growth analysis of the wild type and FtsH
ts
 cells expressing DrrB or DrrAB at 
30 °C or 42 °C was carried out (Figs. 3A and 3B).  The relative growth of various strains at the 
four hour time point was plotted in a histogram (Fig. 3C).   The data in Fig. 3A show that the 
growth of mutant FtsH
ts
 cells is compromised at 42 °C (Fig. 3A; 797, open diamonds; Fig. 3C, 
Column 4) as compared to the growth of wild-type cells under similar conditions (Figs. 3A, 796, 
lines; Fig. 3C, Column 2).  This result is not surprising due to the essential nature of E. coli FtsH.  
Interestingly, the expression of DrrB alone in FtsH
ts
 cells at 42 °C further inhibited the growth of 
these cells (Fig. 3A, compare 797, open diamonds with 797/B, filled triangles; Fig. 3C, Column 
7).  However, growth inhibition was not seen when DrrB was expressed in wild-type cells at 42 
°C (compare 796, lines with 796/B, open rectangles; Fig. 3C, column 6).  Since DrrB 
accumulates in FtsH
ts
 cells but is proteolysed in wild-type cells (Fig. 1B), it allows us to 
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conclude that the growth defect seen in mutant cells is caused by the accumulation of 
unassembled DrrB protein.  Surprisingly, however, growth inhibition was also seen in the FtsH
ts
 
cells expressing DrrA and DrrB together at 42 °C (Fig. 3B, 797/AB, filled triangles; Fig. 3C, 
Column 7).  This effect was unexpected because DrrA and DrrB can be expressed together in the 
wild-type cells at 42 °C without any negative effect on their growth (Fig. 3B, 796/AB, open 
rectangles; Fig. 3C, Column 6).  These data indicate that the DrrAB proteins expressed in FtsH
ts
 
cells at 42 °C may be misfolded, and the accumulation of misfolded membrane proteins results 
in growth inhibition.  It was also observed that if the FtsH
ts
 cells initially induced at 42 °C were 
shifted down to 30 °C, the cell growth resumed, albeit slowly.  After 43 hours of temperature 
shift-down, the final growth was about half as compared to the cells induced and maintained at 
30 °C (data not shown), indicating that the growth inhibition of these cells is quite severe.  In 
summary, the data in Fig. 3 suggest that FtsH is not only responsible for removing unassembled 
DrrB (in the absence of DrrA) but it may also be critical for proper assembly of the DrrAB 
complex in the membrane.   
The growth defect of the FtsH
ts
 cells expressing DrrB or DrrAB at 42 °C could be 
rescued by overexpression of FtsH in trans (Figs. 3A-B, open triangles; Fig. 3C, Column 8), 
indicating that the absence of functional FtsH was solely responsible for this defect.  The growth 
defect in each case was also suppressed by overexpression of the chaperone GroESL (Figs. 3A-
B, filled circles; Fig. 3C, Column 9) but not to the same extent as seen with FtsH.  Western blot 
analysis of the membrane fractions (prepared from the four hour cultures of samples # 6-9 in 
Figs. 3A-B) showed that while FtsH overexpression resulted in significant proteolysis of DrrAB 
(Fig. 3D, lanes 3 and 7), overexpression of GroESL did not (lanes 4 and 8).  This might imply 
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that FtsH restores growth by simply removing misfolded DrrAB proteins, while GroESL is able 
to alter their conformation, thus alleviating growth inhibition.    
FtsH preferentially proteolyzes misfolded DrrAB - To determine if FtsH discriminates 
between properly assembled and misfolded DrrAB, the effect of overexpression of FtsH 
proteolysis was compared in wild type or FtsH
ts 
cells at 30 °C or 42 °C.  Interestingly,  
overexpression of FtsH in either wild type (Figs. 4A-B, compare lanes 1 and 3) or FtsH
ts 
cells 
(lanes 2 and 4) produced no significant proteolysis of DrrA and DrrB expressed at 30 °C, 
showing that FtsH does not proteolyze properly assembled DrrAB.  However, when the DrrAB 
proteins were expressed in wild-type cells at 42 °C, simultaneous overexpression of FtsH 
resulted in significant proteolysis (Figs. 4A-B, compare lanes 3 and 7).  These data suggest that 
the DrrAB proteins must acquire a partially unfolded conformation at a higher temperature (as 
also seen in Fig. 1B), thus making them more susceptible to proteolysis by over-expressed FtsH.  
As expected, overexpression of FtsH in FtsH
ts 
cells also showed significant proteolysis of DrrAB 
expressed at 42 °C (Figs. 4A-B, lanes 4 and 8).  This is consistent with the data in Fig. 3, which 
suggested that the DrrAB proteins expressed at 42 °C in FtsH
ts 
cells are misfolded.  (Please note 
that the conformation of the DrrAB proteins in wild-type cells at 42 °C is completely different 
from the DrrAB expressed in mutant FtsH
ts
 cells at 42 °C even though they are both sensitive to 
overexpressed FtsH.   In a later experiment in Fig. 8, it is shown that the DrrAB proteins 
expressed in wild type cells at 42 °C retain normal function, while the DrrAB expressed in FtsH
ts
 
cells are inactive due to their misfolding)  
The rate of proteolysis of misfolded DrrAB by FtsH was analyzed in a separate time-
course experiment.  The misfolded DrrAB proteins were first allowed to accumulate in the 
membranes of FtsH
ts 
cells by induction with IPTG for 1 hour at 42 °C.  Chloramphenicol was 
19 
added to stop further synthesis, as described under Methods.  The synthesis of FtsH from 
pBADftsH was induced by addition of arabinose, and the proteolysis of DrrA and DrrB by FtsH 
was determined by Western blot analysis.  The data in Figs. 4C and 4D (filled circles) show that 
synthesis of FtsH (Fig. 4E, lower panel) resulted in increasing proteolysis of misfolded DrrA and 
DrrB from the membrane.  At 120 minutes after addition of arabinose, about 75-80% of DrrA 
and DrrB were removed from the membrane.  These observations are in agreement with the 
dislocation model proposed previously for the activity of FtsH (65).  No significant proteolysis 
of DrrAB was seen in the absence of FtsH synthesis (Figs. 4C and 4D, filled rectangles).    
The AAA domain of FtsH contains a chaperone-like activity, but it is not sufficient by itself 
to restore the Dox efflux function - The growth experiment in Fig. 3B suggested that FtsH may 
be critical for the assembly of the DrrAB complex.  Further support for this idea was obtained by 
comparing the rate of assembly of the DrrAB complex in wild type and FtsH
ts
 cells.  The data in 
Fig. 5 show that the assembly of DrrA and DrrB in the membrane of FtsH
ts
 cells is significantly 
compromised already at 30 °C as compared to in the wild type cells.  A significant difference in 
the amounts of DrrAB in the membrane of wild type and mutant cells was seen at all time points 
tested (Fig. 5, compare lanes 1-3 with 7-9).  However, this difference is most evident at the early 
time points, which suggests that the rate of assembly of DrrAB is affected by FtsH.  This is most 
likely due to the partial defect of FtsH function in FtsH
ts
 cells already at 30 °C, leading to the 
low efficiency of the DrrAB complex formation.   
To determine if the ability to promote assembly of DrrAB resides in the AAA domain of 
FtsH, variants containing mutations in the Walker A motif of the AAA domain (K198N 
mutation) or the conserved amino acids in the proteolytic domain (the HEH mutation and the 
AAA subclone are described under Methods) were created.  The K198N allele contained a 
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defective AAA domain, while the HEH mutant and the AAA subclone contained an intact AAA 
domain.  As expected, the K198N mutation resulted in a significantly reduced ATPase activity, 
however the HEH mutant and the AAA subclone were unaffected (Table 2).  The in vitro 
proteolytic activity assay showed that while the wild-type FtsH completely proteolyzed α-casein 
in one hour, no significant reduction in the α-casein level was seen with the HEH mutant even 
after two hours of incubation (Fig. 6).  These analyses confirmed that the AAA and the 
proteolytic domain mutants behave as expected.  Therefore, they were used in two different 
complementation experiments (described below) to determine if the AAA domain by itself is 
sufficient for promoting assembly of the DrrAB complex.   
The expression of the DrrAB proteins in FtsH
ts
 cells was previously shown to result in 
severe growth inhibition (Fig. 3B, filled triangles).  This inhibition was reversed by simultaneous 
expression of FtsH (Fig. 3B, open triangles).  In the next experiment, we asked whether co-
expression of the HEH allele or the AAA subclone can rescue FtsH
ts
 cells from the growth 
inhibition resulting from DrrAB expression.  The data in Fig. 7 show that the simultaneous 
expression of either the HEH mutant (Fig. 7A, open circles) or the AAA subclone (Fig. 7A, filled 
triangles) with DrrAB can complement the growth defect of FtsH
ts
 cells, indicating that the AAA 
domain of FtsH indeed contains a chaperone-like activity.  Interestingly, the HEH mutant 
showed much better complementation of the growth defect as compared to the AAA subclone, 
perhaps due to a more native conformation of the full-length HEH protein as compared to the 
AAA subclone.  The K198N mutation, on the other hand, showed no growth complementation 
effect (Fig. 7A, open triangles), showing that the ATPase activity associated with the AAA 
domain is important for the chaperone function of FtsH.  Western blot analysis showed that the 
DrrAB complex is membrane-associated in the FtsH(HEH), FtsH(AAA), and FtsH (K198N)-
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containing strains (Figs. 7B and 7C, lanes 5-7), and the amounts of DrrA and DrrB in these cells 
were comparable to the levels in their absence (lane 3).  Therefore the restoration of growth by 
the HEH and AAA clones must result from a change in conformation of the DrrAB proteins 
brought about by the functional AAA domain present in these two clones.  Whether the HEH and 
AAA variants of FtsH can also restore function of the DrrAB complex is addressed in the next 
experiment. 
We previously showed that the wild-type DrrA and DrrB proteins together carry out 
ATP-dependent efflux of the anticancer drug doxorubicin (61).  Here, we investigated whether 
co-expression of the AAA subclone or the HEH allele can restore the Dox efflux function of the 
misassembled DrrAB proteins expressed in FtsH
ts
 cells at 42 °C (Fig. 8).  The data in Fig 8A 
indicate that the rate of DrrAB-mediated Dox efflux at 30 °C in the wild-type 796 and FtsH
ts
 797 
cells is comparable (Columns 1 and 3).   Induction of wild-type cells at 42 °C showed only a 
slight reduction in Dox efflux (Column 2), which is likely due to the destabilization effect 
produced by high temperature on DrrAB, as seen earlier in Figs. 1 and 4.  By contrast, the FtsH
ts
 
cells induced at 42 °C showed very little or no DrrAB-mediated Dox efflux (Fig. 8A, column 4), 
which was comparable to the efflux seen with control cells containing empty vector (Fig. 8A, 
Columns 5 and 6).  These data confirm that the DrrAB proteins are misfolded in the absence of 
functional FtsH.  Simultaneous overexpression of the FtsH variants, K198N, HEH or the AAA 
subclone, in FtsH
ts
 cells did not restore function of misassembled DrrAB (Fig. 8B, columns 4-6), 
even though restoration of growth by HEH and the AAA subclone was earlier seen in Fig. 7A.  
Similarly, overexpression of GroESL also did not complement the DrrAB-mediated Dox efflux 
in FtsH
ts
 cells (Fig. 8B, column 7).  One possible explanation for these data could be that even 
though the AAA domain of FtsH (or GroESL) is able to alter the conformation of the DrrAB 
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proteins and relieve growth inhibition, it is not sufficient by itself to restore proper conformation 
required for full function of the complex.   
Wild-type FtsH can refold previously misassembled DrrAB and restore function - 
Surprisingly, co-expression of wild-type FtsH restored the Dox efflux function of the 
misassembled proteins expressed in FtsH
ts
 cells at 42 °C resulting in a significant recovery 
(about 45%) of Dox efflux by the DrrAB complex (Fig. 8B; compare columns 2 and 3).  Since 
this could only have resulted if FtsH expressed in trans facilitated assembly of the complex, 
these results imply that the AAA and the proteolytic domains of FtsH must work hand-in-hand to 
bring about functional assembly of the DrrAB complex.  In this experiment, however, FtsH and 
the DrrAB proteins were expressed simultaneously by IPTG induction, therefore it was not 
possible to determine if FtsH assists only the newly synthesized DrrAB to achieve proper 
conformation, or if it can also bring about refolding of the DrrAB proteins that have already been 
misfolded.  
Therefore, in the next experiment, DrrAB and wild-type FtsH were expressed in FtsH
ts
 
cells in a sequential manner.  The ftsH gene subcloned under the control of the araBAD 
promoter was induced by arabinose, while the drrAB genes remained under the control of the lac 
promoter induced by IPTG.  The FtsH
ts
 cells containing both the plasmids (797/AB/pBADftsH) 
were grown at 30 °C to mid-log phase.  The DrrAB proteins were first induced with IPTG at 42 
°C for 1 hour (this condition inactivates FtsH and renders DrrAB inactive as seen in Figs. 8A and 
8B).  The cells were then washed several times to remove extracellular IPTG and stop further 
synthesis of DrrAB.  The expression of FtsH was induced by arabinose for 1 hour at 42 °C, and 
the cells were subjected to the Dox efflux assay.  To maintain the chromosomally-encoded FtsH 
in an inactive conformation, the temperature was maintained at 42 °C throughout the duration of 
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the experiment.  As previously seen in Fig. 8B, simultaneous expression of DrrAB and FtsH 
resulted in restoration of Dox efflux (Fig. 8C; 797/AB/pUCftsH, column 3).  More interestingly, 
however, even greater restoration of the DrrAB-mediated Dox efflux was seen when FtsH was 
induced after DrrAB proteins had been pre-synthesized in these cells (Fig. 8C, 
797/AB/pBADftsH+ara, column 5).  In the absence of arabinose induction of FtsH, much lower 
restoration of Dox efflux was seen (Fig. 8C, 797/AB/pBADftsH – ara, column 4).  These data, 
therefore, show that the sequential expression of DrrAB and FtsH can still restore the function of 
the previously misfolded DrrAB proteins to the same (or even higher) extent as seen with 
simultaneous expression.  
Finally, the effect of over-expression of FtsH on Dox efflux function of DrrAB expressed 
at different temperatures was investigated.  Irrespective of whether the DrrAB proteins were 
induced at 30 °C, 37 °C, or 42 °C in FtsH
ts
 cells, simultaneous expression of FtsH resulted in a 
very similar final Dox efflux efficiency (Fig. 8D).  At 42 °C, co- expression of FtsH enhanced 
Dox efflux of misfolded DrrAB 5-fold (compare columns 3 and 6), yielding about 45% Dox 
efflux efficiency.  Interestingly, over-expression of FtsH at 30 °C or 37 °C reduced the efficiency 
by about half (compare columns 1-2 with 4-5), once again yielding final Dox efflux efficiency of 
about 45%.  These results imply that FtsH produces an optimal level of functional complexes in 
the membrane perhaps by exerting both proteolytic and refolding effects concurrently.   
2.4 Discussion 
Non-native proteins, especially unassembled membrane proteins, interfere with cellular 
processes and are known to become toxic to the cells.  Therefore, quality control systems, 
consisting of chaperones and proteases, play essential roles by monitoring their folding and 
either refolding or degrading misfolded proteins (78-80).  Hsp60 (GroEL/ES) and Hsp70 (DnaK) 
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proteins provide classical examples of ATP-dependent chaperones which prevent aggregation of 
newly translated proteins and promote their refolding (79).  A special class of chaperones (e.g. 
ClpB in bacteria and its homologs Hsp78 and Hsp104 in eukaryotes) is known to resolubilize 
protein aggregates and, in cooperation with the Hsp70 chaperones (specifically DnaKJE), can 
result in regaining function of the affected protein (72).  On the other end of the spectrum are 
proteins classically defined as proteases, for example Lon, ClpA/P, ClpX/P and FtsH, whose 
major function is considered to be removal of irreversibly damaged proteins from the cell 
(63,71,81).  Despite their differences, however, both classical chaperones and proteases share 
common features.  For example, both have the ability to recognize and bind non-native 
polypeptides and both bring about unfolding of their substrates, which are subsequently refolded 
(by a chaperone) or degraded (by a protease)(69,79,82).  Because of the ATP-dependent 
unfolding function of AAA+ proteases, it has been speculated that they may also have the ability 
to refold substrate proteins and may participate in protein biogenesis.  However, very little direct 
evidence is available for the role of FtsH or other AAA
+
 proteases in biogenesis, especially of 
membrane protein complexes.   In this study, we provide clear evidence that the E. coli FtsH is 
able to both degrade and refold misassembled DrrAB proteins, resulting in regaining the Dox 
efflux function of the membrane complex.   
We show that in the absence of the DrrA protein, DrrB acquires an FtsH-sensitive 
conformation and is completely proteolyzed.  However, in the absence of functional FtsH, the 
DrrB protein accumulates even in the absence of DrrA confirming that FtsH monitors the folding 
status of DrrB and removes it if it is improperly assembled.  The molecular details of proteolysis 
of DrrB by FtsH are currently unknown, however based on the prevalent model for its action 
(65,83) we assume that FtsH could initiate proteolysis of DrrB either at the N- or the C-terminal 
25 
end (both of which are found in the cytoplasm, (84)).  Cross-linking studies previously showed 
that the N terminus of DrrB is the major site of interaction with DrrA (61,84); therefore we 
propose that proteolysis of DrrB initiates at its N- terminal tail, and binding of DrrA to this 
region of DrrB protects it from proteolysis by FtsH. 
Interestingly, we found that the function of FtsH is not limited to proteolysis of 
unassembled DrrB, but it also plays an essential role in folding and assembly of the DrrAB 
complex.  This conclusion is supported by several lines of evidence presented in this paper.  
First, the expression of DrrA and DrrB together in FtsH
ts
 cells at 42 °C (which results in 
inactivation of FtsH) was found to be growth inhibitory (Fig. 3B) suggesting that the complex is 
improperly assembled in the absence of a functional FtsH.  Second, the rate of assembly of the 
DrrAB complex in the FtsH
ts
 cells at 30 °C was found to be significantly reduced as compared to 
the wild-type cells (Fig. 5).  Third, functional analysis showed complete absence of the DrrAB-
mediated Dox efflux in FtsH
ts
 cells under conditions of FtsH inactivation, suggesting that most 
or all of the DrrAB proteins expressed in these cells at 42 °C are misassembled.  By contrast, the 
DrrAB proteins expressed in wild-type cells at 42 °C retained on average 85-90% of the Dox 
efflux activity (Fig. 8A).  Finally, co-expression of FtsH in trans in FtsH
ts
 cells restored the 
ability of DrrAB to carry out Dox efflux, confirming that FtsH facilitates assembly of the DrrAB 
complex (Fig. 8B).  Nevertheless, this result was surprising because FtsH contains a functional 
proteolytic domain.  It’s overexpression in FtsHts cells results in proteolysis of the misfolded 
DrrAB proteins (as seen in Fig. 4), however the data in Fig. 8B show that FtsH also facilitated 
some folding resulting in about  45% recovery of the Dox efflux activity.  Either the AAA 
domain by itself or the GroESL chaperone was unable to complement the Dox efflux function of 
DrrAB in FtsH
ts
 cells, even though each was able to alleviate the growth defect.  Therefore, 
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together these data suggest that both the AAA and the protease domains of FtsH are essential for 
promoting functional assembly of DrrAB.  
The most crucial evidence for the refolding function of FtsH, however, came from the 
sequential expression studies.  Irrespective of whether FtsH was expressed simultaneously with 
DrrAB or expressed after the non-functional DrrA and DrrB proteins had already accumulated in 
FtsH
ts
 cells, it was able to restore the function of the complex (Fig. 8C), thus showing 
conclusively that FtsH not only facilitates assembly of the DrrAB complex but it is also actively 
involved in refolding previously misassembled DrrAB proteins.  Interestingly, we also found that 
the sequential expression of DrrAB and FtsH resulted in a significantly higher recovery of the 
Dox efflux function of DrrAB as compared to simultaneous expression (Fig. 8C).  This finding 
suggests that FtsH treats its substrate differently during its synthesis as compared to after it has 
already been synthesized.   
In summary, our studies confirm that the AAA domain of FtsH can recognize and bind 
substrates and change their conformation, which is in agreement with the previous studies (75).  
However, we also show that the two activities (ATPase and proteolytic) of FtsH must be present 
simultaneously and occur in a coordinated manner to facilitate assembly and refolding of DrrAB.  
Much more extensive analysis will be required in the future to understand the nature of the 
molecular processes involved in refolding of DrrA and DrrB and to determine if other factors 
also play a role in the assembly of the DrrAB complex.  Further studies will also provide clues 
about how degradation and assembly of multi-subunit complexes are regulated, and whether 
other AAA+ proteases may also contain chaperone activity.  This study raises intriguing 
questions about the distinction between classical chaperones like GroESL (that can prevent 
aggregation of many proteins) and the classical proteases like FtsH that not only carry out 
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proteolysis but also actively participate in refolding of their specific substrates, as shown in this 
study.  Bukau and Mogk previously (79) coined four terms to describe the various activities of 
chaperones and proteases: Holders (small heat shock proteins, Hsps), Folders (GroESL and 
DnaK), Unfolders (ClpA, ClpX, and ClpB), and Proteases (Lon, ClpP, and FtsH).  In light of the 
findings reported in this article, we propose a new term ‘Specific Refolder’ to describe the 
function of FtsH and possibly other AAA+ proteases that may be shown in the future to contain 
such an activity.     
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Table 2.1 Baterial strains, plasmids and anti-sera 
 
Table 2.2 The ATPase activity of purified FtsH and its variants 
 
 
 
 
  
Name Description Reference or 
Source 
Bacterial Strains 
TG1 K-12 Δ(lac-pro) supE thi hsdD5/F’ tra36 proA
+
B
+ 
lacI
q
 
lacZΔM15 
(85) 
HMS174(DE
3) 
F
-
 recA1 hsdR (rK12- mK12+) (DE3) (Rif R) (85) 
AR796 F
-
, zhd-33::Tn10, araD139, (argF-lac)U169, rpsL150, rpsE, 
relA1, f1bB5301, deoC1, ptsF25, rbsR, zgj3198::Tn10kan. 
(54) 
AR797 F
-
, zhd-33::Tn10, araD139, (argF-lac)U169, rpsL150, rpsE, 
relA1, f1bB5301, deoC1, ptsF25, rbsR, zgj3198::Tn10kan. 
ftsH1 
(54) 
SG1110 Δlon-510, zba-1091:: ΔTn10(λ) (86) 
SG1126 Δarg, clpA319:: Δkan (86) 
Plasmids 
pSU2718 Cloning vector, pACYC184 derivative, Cm
r
 (59) 
pKY326 groES/groEL in pHSG575, Cm
r
 (76) 
pDX101 drrAB in pSU2718, Cm
r
 (59) 
pDX103 drrB in pSU2718, Cm
r
 (59) 
pUCftsH ftsH  in pUC18, Amp
r
, restriction sites: EcoRI, HindIII This study 
pUCftsH(K19
8N) 
pUC18 containing ftsH with mutation of Lys
198
 to Asn, Amp
r
 This study 
pUCftsH(HE
H) 
pUC18 containing ftsH with  mutations of His
417
Glu
418
His
421 
 
to Ala
417
Gln
418
Ala
421
, Amp
r
 
This study 
pUCftsH(AA
A) 
pUC18 containing ftsH with deletion of proteolytic domain, 
Amp
r
 
This study 
pUCgroESL groES/groEL in pUC18, Amp
r
, restriction sites: NdeI, 
HindIII 
This study 
pETftsH ftsH in pET28a with C-terminal histag, Kan
r
 This study 
pETFftsH(K1
98N) 
ftsH(K198N) in pET28a with C-terminal histag, Kan
r
 This study 
pETftsH(HEH
) 
ftsH(HEH) in pET28a with C-terminal histag, Kan
r
 This study 
pETftsH(AAA
) 
ftsH(AAA) in pET28a with C-terminal histag, Kan
r
 This study 
pBADftsH ftsH in pBAD/HisA, Amp
r
 This study 
FtsH Variant ATPase activity (nmol Pi/min/mg) 
Wild-type FtsH             139.5 
FtsH(K198N)               18.1 
FtsH(HEH)             147.8 
FtsH(AAA)             155.6 
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Figure 2.1 Role of DrrA and FtsH in stable maintenance of DrrB 
 
FIGURE 2.1 Role of DrrA and FtsH in stable maintenance of DrrB. (A) DrrA is required 
for stable expression of DrrB.  Wild-type E.coli (TG1) cells expressing DrrAB (pDX101) or 
DrrB alone (pDX103) were grown at 37° C to mid-log phase (A600nm=0.6) and induced with 0.25 
mM IPTG for 3 h.  30 µg membrane proteins were loaded onto 12% SDS-PAGE gels, followed 
by Western blotting against anti-DrrA (upper panel) and anti-DrrB (lower panel) antibodies.  (B) 
FtsH is responsible for proteolysis of unassembled DrrB.  Wild-type E. coli (796) or the E. 
coli 797 (ftsH
ts
) cells expressing DrrAB (pDX101) or DrrB alone (pDX103) were grown at 30 °C 
to mid-log phase and induced with 0.25 mM IPTG at either 30 °C or 42 °C for 3 h.  Western blot 
analysis of the membrane fraction was carried out as in Fig. 1A.  (C) ClpA/P or the Lon 
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protease is not involved in quality control of DrrB. Wild-type E. coli (796), E. coli 797 
(ftsH
ts
), E. coli SG1110 (Lon
-
), and E. coli SG1126 (ClpA
-
) cells expressing DrrAB (pDX101) or 
DrrB alone (pDX103) were grown at 30 °C or 37 °C to mid-log phase and induced with 0.25 
mM IPTG at either 42 °C or 37 °C for 3 h, as indicated.  Analysis was carried as described in (B) 
above.   
 
 
 
Figure 2.2 Western blot analysis of the cytosol, membrane, and inclusion body fractions of 
E. coli 796 or 797 cells expressing DrrAB at 30 °C or 42 °C. 
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FIGURE 2.2 Western blot analysis of the cytosol, membrane, and inclusion body fractions 
of E. coli 796 or 797 cells expressing DrrAB at 30 °C or 42 °C.  Wild-type E. coli 796 or the 
E. coli 797 (ftsH
ts
) cells expressing DrrAB (pDX101) were grown at 30 °C to mid-log phase and 
induced with 0.25 mM IPTG at either 30 °C or 42 °C for 3 h.  Cell fractions were prepared, as 
described under Methods.  20 µg of each fraction was loaded onto 12% SDS-PAGE gels, 
followed by Western blotting against anti-DrrA (upper panel) and anti-DrrB (lower panel) 
antibodies.  (m, membrane; c, cytosol; IB, inclusion body).  Note that the anti-DrrB antibody is 
an anti-peptide antibody, therefore it shows some cross-reactivity with epitopes in other E. coli 
proteins, as explained in a previous publication (59). 
 
Figure 2.3 Growth inhibition resulting from expression of DrrB alone or DrrAB together in E. 
coli 797 cells can be relieved by the overexpression of FtsH or GroESL. 
These data were contributed by Wen Li and Divya K. Rao 
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FIGURE 2.3 Growth inhibition resulting from expression of DrrB alone or DrrAB together 
in E. coli 797 cells can be relieved by the overexpression of FtsH or GroESL. (A) Effect of 
overexpression of FtsH or GroESL on growth of 797 cells expressing DrrB.  797 cells 
containing pDX103 (DrrB) and pUCftsH or pUCgroESL were grown at 30 °C and induced at 42 
°C, as in Fig. 1B.  The growth was monitored at O.D. 600 nm for four hours after induction.  (B) 
Effect of overexpression of FtsH or GroESL on growth of 797 cells expressing DrrAB.  797 
cells containing pDX101 (DrrAB) and pUCftsH or pUCgroESL were anayzed, as described in 
(A) above.  (C) Quantitation of the growth of 796 or 797 cells expressing DrrB or DrrAB at 
4 hours after induction. The growth of the sample #1 at 4 hours in Fig. 3A or 3B was 
designated as 1.0.  The relative growth of each culture at 4 hours was calculated.  The histogram 
represents an average of 3 experiments.  Columns 1-9 correspond to the cultures 1-9 in Figs 3A 
(filled) and 3B (open).  (D) Western blot analysis.  The membrane fractions were prepared from 
sample #s 6-9 collected at the 4 hour time point in Fig. 3A and 3B.  Western blot analysis was 
carried out as in Fig. 1(A).   
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Figure 2.4 FtsH preferentially degrades misfolded DrrAB. 
 
 
FIGURE 2.4  FtsH preferentially degrades misfolded DrrAB.  (A) E. coli 796 or 797 cells 
containing pDX101(DrrAB) and  pUCftsH were grown and analyzed by Western blotting, as in 
Fig. 1A.  (B) Quantitative analysis of the amounts of DrrA and DrrB.  The intensity of the 
bands on the nitrocellulose membrane in Fig. 4A was determined by densitometric scanning.  
The intensity of DrrA and DrrB in lane 1 was designated as 1.  The data represent an average of 
3 experiments.  Columns 1-8 correspond to the lanes 1-8 in Fig. 4A.  (C), (D) and (E) In vivo 
FtsH proteolytic assay.  The assay was carried out as described under Methods.  The membrane 
fractions were prepared from the cells collected at the indicated time points after addition of 
arabinose.  20 µg total membrane protein was loaded onto 12% SDS-PAGE, followed by 
Western blot with anti-DrrA, anti-DrrB, or anti-FtsH antibodies.  The intensity of the bands on 
the nitrocellulose membrane was determined by densitometric scanning.  The intensity of DrrA 
and DrrB on the membrane at 0 min was designated as 1.0.  (C) Quantitation of DrrA in the 
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membrane at the indicated time points after addition of arabinose.  The data shown represent an 
average of 3 experiments.  (D) Quantitation of DrrB in the membrane.  (E) Western blot analysis 
showing amount of FtsH present in the membrane at various times after addition of arabinose.  
Top panel:  cells containing pBAD vector only.  Bottom panel: cells containing the plasmid 
pBADftsH.   
 
 
Figure 2.5 FtsH promotes assembly of the DrrAB complex 
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FIGURE 2.5 FtsH promotes assembly of the DrrAB complex.  (A) E. coli 796 or 797 cells 
expressing DrrAB were grown at 30 °C to mid-log phase and the culture was divided into two 
halves.  One half was induced  with 0.25 mM IPTG at 30° C (lanes 1-3 for 796 and  lanes 7-9 for 
797) and  the other half was induced at 42 °C (lanes 4-6 for 796 and lanes 10-12 for 797).  
Aliquots of each sample were collected at 30 min intervals. Hours of induction are shown at the 
top of the gel. 0 hour represents A600nm = 0.6 at which time IPTG was added.  Western blot 
analysis was carried out as in Fig. 1A.  (B) The quantitative analysis of DrrA and DrrB.  The 
intensity of bands on the nitrocellulose membrane was determined by densitometric scanning.  
The intensity of DrrA and DrrB in lane 1 was designated as 1.  The data represent an average of 
3 experiments. 
 
 
Figure 2.6 In vitro digestion of α-casein by purified FtsH or FtsH(HEH) 
 
FIGURE 2.6 In vitro digestion of α-casein by purified FtsH or FtsH(HEH).  (A) α-casein was 
mixed with purified wild-type FtsH or FtsH (HEH) protein in the protease buffer as described in 
the Methods.  The samples were analyzed by 12% SDS-PAGE, followed by Coomassie Brilliant 
blue staining.  (B) Quantitative analysis of the amounts of α-casein.  The intensity of the 
bands on the nitrocellulose membrane was determined by densitometric scanning.  The intensity 
of α-casein in lane 1 was designated as 1.  The intensities represent an average of 3 experiments.  
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Figure 2.7 The AAA domain of FtsH is sufficient to complement the growth defect 
resulting from the expression of DrrAB in 797 cells. 
These data were contributed by Wen Li and Divya K. Rao 
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FIGURE 2.7 The AAA domain of FtsH is sufficient to complement the growth defect 
resulting from the expression of DrrAB in 797 cells.  E. coli 797 cells containing the drrAB 
genes (pDX101) and the wild-type or a mutated version (K198N, HEH, or AAA subclone) of the 
ftsH gene on a compatible plasmid were grown at 30 °C and induced at 42 °C, as in Fig. 1B.  (A) 
Growth analysis at 600 nm. (B) Western blot analysis.  Membranes prepared from the cells 
collected at the 3 hour time point were analyzed, as in Fig. 1A.  (C) Quantitative analysis of 
DrrA and DrrB.  The intensity of the bands on the nitrocellulose membrane in Fig. 7B was 
determined by densitometric scanning.  The intensity of DrrA and DrrB in lane 1 was designated 
as 1.0.  The data shown represent an average of 3 experiments.  The columns 1-8 correspond to 
samples 1-8 in Fig. 7B.  
  
 
Figure 2.8 DrrAB-mediated Dox efflux. 
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FIGURE 2.8  DrrAB-mediated Dox efflux.  (A) Dox efflux in E. coli 796 or 797 cells.  The 
cells containing pDX101 (DrrAB) or the empty vector were grown at 30 °C to mid-log phase and 
induced with 0.1 mM IPTG at either 30 °C or 42 °C for 1 h.  The washed cells were loaded with 
Dox, and efflux was initiated by addition of glucose and detected fluorometrically.  The slope of 
the efflux curve of sample 1 in each panel was designated as 1.0.  The efficiency of Dox efflux 
was then calculated by dividing the slope of each efflux curve by the slope of sample 1.  The 
average data obtained from three independent experiments are shown in the histograms.  (B) 
Complementation of the DrrAB-mediated Dox efflux in 797 cells by simultaneous 
overexpression of wild-type FtsH or its variants.  E. coli 797 cells containing 
pDX101(DrrAB) and  pUCftsH (wild-type FtsH), pUCftsH(K198N), pUCftsH(HEH), 
pUCftsH(AAA) or pUCgroESL, were analyzed as described under (A) above.  (C)  Effect of 
sequential expression of DrrAB and FtsH on complementation of Dox efflux.  E. coli 797 
cells containing pDX101 (DrrAB) and pBADftsH were grown at 30 °C to mid-log phase and 
induced with 0.1mM IPTG for 1 h at 42 °C.  The cells were washed extensively to remove IPTG 
and divided into two halves.  One half was kept at 42 °C for 1 h without any induction (-ara, 42 
°C) and the other half was induced by 1% arabinose at 42 °C (+ara, 42 °C) for 1 h.  As controls, 
796/AB, 797/AB and 797/AB/pUCftsH were grown at 30 °C to mid-log phase and induced with 
0.1 mM IPTG at 42 °C for 2 h.  The cells were loaded with Dox, and efflux was measured.   The 
data were analyzed as described under (A) above.  (D)  Effect of simultaneous over-expression 
of FtsH on Dox efflux by DrrAB proteins expressed at different temperatures. 797 cells 
containing pDX101 (DrrAB) and pUCftsH were grown at 30 °C to O.D. 0.6, induced with 0.1 
mM IPTG at 30 °C, 37 °C or 42 °C for 1 h, and analyzed as in (A) above. 
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3 THE DrrAB SYSTEM OF STREPTOMYCES PEUCETIUS IS A MULTI-DRUG 
TRASNPORTER OF A BROAD SUBSTRATE SPECIFICTY 
2.5 Introduction 
Multidrug resistance (MDR) has emerged as a major clinical problem in recent years both 
for the treatment of infectious diseases and for chemotherapy of cancer.  Although many 
different mechanisms for drug resistance are known, a common strategy consists of active efflux 
of drugs from the cells (87).  Drug transporters are categorized into either single-drug efflux 
systems (which are specific for a drug or a group of drugs) or multi-drug efflux systems that 
exhibit a broad specificity and can transport structurally and functionally unrelated compounds.  
These proteins function as either primary active (belonging to the ATP Binding Cassette 
superfamily) or secondary active transporters (88).  The phenomenon of multidrug resistance 
was first characterized in mammalian cancer cells, where exposure to anticancer drugs was seen 
to result in over-expression of ABC-type efflux pumps, such as P-glycoprotein and MRP1 (88).  
These proteins have since been shown to transport hundreds of structurally unrelated 
compounds, including amphipathic anti-cancer drugs, peptides, and fluorescent dyes, etc., thus 
conferring MDR in cancer cells.  MDR is also widespread among bacteria - the best known ABC 
family members include the bacterial proteins LmrA and LmrCD in L. lactis, Sav1866 in S. 
aureus, and MsbA in E. coli.   
While most of the ABC proteins mentioned above have served as useful models to 
characterize and understand the basis of MDR (7,88), the most extensive biochemical analysis of 
the nature of multidrug specificity has been carried out with Pgp (89,90).  Together the analyses 
carried out by many different groups suggested that Pgp contains a large drug binding chamber 
which can accommodate several drugs simultaneously. It was also suggested that the drug 
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binding chamber in Pgp is lined by several trans-membrane (TM) helices, including TMs 4-6 in 
TMD1 and TMs 9-12 in TMD2 (89).  Most recently, the crystal structure of Pgp confirmed many 
findings of the biochemical analysis and showed that Pgp indeed contains a large and flexible 
drug binding cavity made of mostly hydrophobic and aromatic residues (42).  Different drugs 
were seen to interact with residues in different parts of the flexible cavity, mostly through 
hydrophobic interactions, thus providing an explanation for the poly-specific nature of Pgp.  The 
crystal structure of Pgp also revealed that some drugs were bound to a single site, while some 
others bound to two different locations within the cavity.  The drug binding cavity of Pgp was 
found to reside within the cell membrane, and it showed the presence of two portals formed by 
TMs 4 and 6 and TMs 10 and 12 which allow direct entry of hydrophobic molecules from the 
membrane (42).  This observation supports previous models, which proposed that Pgp can 
extract drugs directly from the lipid bilayer and remove them by a hydrophobic vacuum cleaner 
mechanism (17).  The crystal structure of another MDR protein, AcrB, a secondary-active 
transporter, is also available.  This structure also showed the presence of a very large central drug 
binding cavity, which could accommodate several ligand molecules simultaneously (91).  
However, the drug binding cavity, though present in the membrane, was found to be accessible 
to the periplasmic domain.  Thus, in contrast to Pgp (where the drug portals are located in the 
membrane), the periplasmic region of AcrB seems to play a major role in determining substrate 
specificity, suggesting differences between the mechanisms of different MDR proteins. 
The bacterial ABC drug transporters that have also been studied in significant detail 
include the E. coli ABC transporter MsbA (responsible for export of Lipid A, the core moiety of 
LPS), L. lactis homologue LmrA and S. aureus Sav1866 (5,7,92).  All of these proteins have 
been shown to transport multiple drugs.  Interestingly, MsbA was found to contain overlapping 
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substrate specificity with LmrA and Sav1866 (93).  Some newly identified members, such as 
VcaM from Non-O1 Vibrio cholerae and the YccC (BmrA) from Bacillus subtiliswere also 
shown to transport multiple drugs (94,95).  Therefore, a significant progress has indeed been 
made in understanding the phenomenon of multidrug resistance.  However, the available 
information is based on the analysis of only a handful of drug transporters described above.  
Most other annotated drug transporters, especially those found in the antibiotic/drug producer 
organisms, have not been analyzed for their ability to confer MDR.  Moreover, not much is 
known about why and how the ability to confer multidrug resistance evolves.   
In this study, we analyzed the ABC transporter DrrAB, which confers self-resistance to 
two related anticancer antibiotics doxorubicin (Dox) and daunorubicin (Dnr) in the producer soil 
organism Streptomyces peucetius.  The genes for this system are present in an operon located 
within the gene cluster for biosynthesis of Dox and Dnr, therefore they code for a dedicated 
transporter for these antibiotics.  The DrrAB system represents the simplest form of an ABC 
drug transporter, which is assembled from two molecules each of DrrA (the catalytic subunit) 
and DrrB (integral membrane subunit) (49).  In the mammalian Pgp, the two catalytic and two 
integral membrane domains are naturally fused into a single large polypeptide, possibly the result 
of an evolutionary gene fusion event (4).  Both DrrAB and Pgp confer resistance to the 
anticancer agents Dox and Dnr: DrrAB in the producer organism and Pgp in cancer cells.  
Therefore, the overall structure and function of the DrrAB transporter bears significant similarity 
to Pgp even though these two transporters belong to different classes of ABC proteins (50).   
Subcloning of the drrAB locus in E. coli was previously shown to confer doxorubicin resistance 
in this host (48).  It was also previously shown that the DrrAB system confers resistance to Dox 
by an energy-dependent efflux mechanism (58).  However, it is not known if this system is 
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specific for Dox and Dnr, or if, like Pgp, it can also recognize and transport multiple drugs.  
Since this is a prototype drug resistance mechanism found in the producer organism, analysis of 
this system could shed light on the nature of substrate specificity and elucidate how the ability to 
confer multidrug resistance evolves in proteins.   
In this paper, we provide in-depth characterization of drug transport by the DrrAB system 
and show that, contrary to the generally held assumption, this system forms a multidrug 
transporter.  Using both E. coli whole cells and inside-out membrane vesicles (IOVs), it is shown 
that the DrrAB system can efficiently transport not only Dox, but also Hoechst 33342 and 
ethidium bromide, two substrates most commonly used to establish the MDR phenotype (5,7,27).  
We also found that the DrrAB-mediated Dox efflux is inhibited by a number of other well-
characterized MDR substrates, such as verapamil, rifampicin, vinblastine and colchicine, 
suggesting that these drugs are also substrates of the DrrAB pump.  Interestingly, DrrAB-
mediated efflux could be coupled to the energy of either ATP or GTP hydrolysis, and, as 
expected, the function of this transporter was found to be completely independent of the proton 
motive force (pmf).  Since multiple drugs were found to inhibit Dox efflux by the DrrAB system, 
kinetics analysis was carried out to understand the mechanism of inhibition and interaction of 
drugs with DrrAB.  Our studies revealed that inhibition of Dox efflux by Hoechst 33342 and 
rifampicin occurs by a competitive mechanism, whereas verapamil inhibits Dox transport by a 
non-competitive mechanism, suggesting that the DrrAB transporter may contain at least two 
drug binding sites.  The findings of this paper demonstrate for the first time that the dedicated 
Dox transport system, DrrAB, can recognize and transport multiple drugs.  This study highlights 
overlaps between the substrate specificity of the DrrAB system and Pgp and points to a common 
mechanism, and perhaps origin, for most MDR proteins. 
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2.6 Materials and Methods 
Materials used – verapamil, vinblastine, rifampicin, doxorubicin hydrochloride, ethidium 
bromide, quinine, quinidine, colchicine, succinate, sodium fluoride, NADH (β-Nicotinamide 
adenine dinucleotide reduced disodium salt hydrate), ATP, GTP, and sodium o-vanadate were 
purchased from Sigma Aldrich.  Hoechst 33342, rhodamine 123, rhodamine 6G, rhodamine B, 
and TMRM (Tetramethylrhodamine) were obtained from Life Technology.  Creatine kinase and 
creatine phosphate were purchased from Roche Diagnostics.  
In vivo Dox efflux in cells – E. coli LE392ΔuncIC cells (Table 1) containing either vector 
pSU2718 or pDX101(pSU2718/drrAB) were grown in 200 ml TEA medium [50 mM 
triethanolamine HCl, pH 6.9, 15 mM KCl, 10mM (NH4)2SO4, 1mM MgSO4] supplemented with 
0.5% (w/v) glycerol, 2.5 µg/ml thiamine, 0.5% (w/v) peptone and 0.15% (w/v) succinate to mid-
log phase and induced with 0.1 mM IPTG for 1 hr.  The harvested cells were washed twice and 
resuspended in 100 µl TEA buffer.  10 μl of the cell suspension from above was incubated in 3 
ml of TEA medium containing 10 μM doxorubicin and 5 mM 2,4-dinitrophenol for 11 h at 37 
°C.  The loaded cells were washed twice with 0.1 mM MOPS buffer, pH 7.0 and resuspended in 
3 ml of MOPS buffer containing 2 mM MgSO4.  The fluorescence spectra were recorded on an 
Alphascan-2 spectrofluorometer (Photon Technology International, London, Ontario, Canada).  
The excitation wavelength for doxorubicin was 480 nm, and emission was monitored at 590 nm.  
The excitation and emission slit widths were both set at 1.00 mm, and a time-based script was 
run.  After an initial recording of fluorescence for 100 s at 37 °C, energy was provided in the 
form of either 20 mM glucose or 20 mM succinate, and recording was continued for an 
additional 400 s.  The rate of Dox efflux was determined from the slope in the steady-state range 
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(300 s to 500 s).  Where indicated, 10 mM sodium fluoride was added as inhibitor of ATP 
synthesis. 
In vivo ethidium bromide (EtBr) efflux in cells – E. coli LE392ΔuncIC cells containing the 
indicated plasmid were grown, induced, and loaded with various concentrations (1 µM to 100 
µM) of EtBr, as described above, except that the loading time used was 1 hr at 37 °C.  The 
loaded cells were washed twice with 0.1 mM MOPS, pH 7.0 and resuspened in 3 ml MOPS 
buffer containing 2 mM MgSO4.  EtBr efflux from loaded cells was measured fluorometrically 
(exi, 500 nm; emi, 580 nm) on an Alphascan-2 spectrofluorometer (Photon Technology 
International).   After 100 s, energy was provided in the form of 20 mM glucose.  The recording 
was continued for additional 400 s.  The rate of EtBr efflux was determined from the slope in the 
steady-state range (300 s to 500 s).   
Preparation of inside-out membrane vesicles (IOVs) – E. coli LE392ΔuncIC cells containing 
indicated plasmids were grown in 1 L LB medium at 37 °C until mid-log phase and induced with 
0.25 mM IPTG at 37 °C for 3 hr.  The cells pellet was re-suspended in 20 ml 1xPBS buffer, pH 
7.4 and lysed with French Press at 16,000 p.s.i. twice.  The membrane fraction was prepared 
according to the previously published protocol (49), except that the membrane vesicles were 
washed twice with 20 ml 1xPBS buffer.   
In vitro Dox efflux in IOVs and kinetic analysis – 250 µg IOVs were resuspended in 3 ml 1x 
PBS buffer, pH 7.4 supplemented with 0.1 mg/ml creatine kinase and 5 mM creatine phosphate.  
Dox was added to a final concentration of 1.0 µM, or as indicated.  The fluorescence spectra 
were recorded on an Alphascan-2-spectrofluorometer with excitation wavelength of 480 nm and 
emission wavelength of 590 nm.  The excitation and emission slit width were set to 1.00 mm and 
data were collected at 0.1-s intervals.  After 100 s, the detection was paused, 1 mM Mg
2+
 and 1 
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mM ATP, pH7.5 were added into the reaction and the detection was continued for additional 400 
s.  Where indicated, ATP was substituted with 1 mM GTP or 5 mM NADH.  The rate of Dox 
transport was determined from the slope of the initial linear range between 100 s and 200 s.  To 
determine the kinetics of Dox transport, efflux was measured at a wide range of Dox 
concentrations (0.1 µM to 6 µM).  The data were fitted by the Michaelis–Menten equation (V = 
Vmax[S]/(Km) + [S]) by Sigma Plot Kinetics software in Single-Substrate Format.  
In vitro Hoechst 33342 Efflux in IOVs – The DrrAB-mediated efflux of Hoechst 33342 was 
studied in IOVs, as described above for Dox Efflux with some modifications.  Briefly, 250 µg 
IOVs were resuspended in 3 ml 1x PBS buffer, pH 7.4 supplemented with 0.1 mg/ml creatine 
kinase and 5 mM creatine phosphate and various concentrations of Hoechst 33342 (0.1 µM to 
2.5 µM).  The excitation and emission wavelengths of Hoechst 33342 were 355 nm and 457 nm, 
respectively.  The rate of Hoechst 33342 transport was determined from the initial slope of the 
linear range between100 s to 200 s.   
Vanadate inhibition of Dox efflux in IOVs – 250 µg IOVs were resuspended in 3 ml 1x PBS 
buffer, pH 7.4 supplemented with 0.1 mg/ml creatine kinase, 5 mM creatine phosphate, 1 µM 
Dox, and various concentrations of sodium o-vanadate (0 µM – 100 µM).  The measurement of 
Dox efflux was performed, as described above.  The rate of Dox transport was determined from 
the slope of the linear range between 100 s and 200 s.   
Determination of IC50 – 250 µg IOVs were resuspended in 3ml 1xPBS buffer, pH 7.4 
supplemented with 0.1 mg/ml creatine kinase and 5 mM creatine phosphate, 1 µM Dox, and 
various concentrations of the inhibitory drug.  The measurement of Dox efflux was performed, as 
described above.  The rate of Dox transport was determined from the slope of the initial linear 
range between 100 s and 200 s.  Designating the efflux rate of the sample without inhibitor as 
46 
1.0, the relative rate of each sample was calculated.  The average data of three independent 
experiments were plotted by ‘Scatter Plot with simple error bars’ in Sigma Plot 11.0 software 
and fitted by the dynamic curve fit (equation: y = ae
-bx
, x: concentration of inhibitor; y: relative 
rate).  The IC50 value was determined based on the concentration of the drug that brings about 
50% inhibition of the DrrAB-mediated Dox efflux at a Dox concentration of 1 µM.  
Kinetics of Dox efflux inhibition by known MDR substrates – To study the kinetic inhibition 
of Dox efflux by Hoechst 33342, four different concentrations of Dox (0.25, 0.5, 0.75 and 1.0 
µM) were individually mixed with a fixed concentration of Hoechst 33342 in 1x PBS buffer 
containing 250 µg IOVs, 0.1 mg/ml creatine kinase and 5 mM creatine phosphate.  In total, four 
different concentrations of Hoechst 33342 (0, 0.2, 0.6 or 0.8 µM) were studied.  Similar assays 
were set up to study kinetics of Dox inhibition by different drugs.  Initial rate of Dox transport 
was determined, as described above.  The rate of Dox transport obtained with 1 µM Dox and 0 
µM Hoechst 33342 (or another drug) was designated as 1.0. The relative rates were then 
calculated for each efflux curve, and the data were plotted by Lineweaver-Burk plot using 
SigmaPlot - Kinetics software in Single-Substrate/Single-Inhibitor Kinetics Format.  The error 
bars represent three independent experiments.  The type of inhibition was determined based on 
the AICc value (Akaikes Information Criterion corrected); lower AICc values correspond to 
better fits to the data.   
Point Mutations in DrrA – Site-directed mutagenesis of the drrA gene was carried out by a 
QuikChange Multisite-directed mutagenesis kit (Stratagene, La Jolla, CA). Using pDX101 
(pSU2718/drrAB) plasmid as the template, Gln197, located in the Switch motif of DrrA, was 
changed to Histidine. The resulting plasmid was named pDX101(Q197H).  Another plasmid, 
generated by substituting Tyr198 to Arginine, was named pDX101(Y198R).  Double mutations 
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of Gln197Tyr198 to His197Arg198
 
and
 
His197His198
 
were also created, and these plasmids 
were named pDX101(Q197H/Y198R; HR) and pDX101(Q197H/Y198H; HH).  Other mutations 
used in this study were described previously (Table 1). 
ATPase activity in IOVs - 7.5 µg IOVs expressing either wild type DrrAB or DrrAB with 
mutations in the Switch motif were incubated in 1 ml reaction mixture containing 50 mM MOPs, 
pH 7.5, 1mM dithiothreitol, 10µl PK/LDH enzyme (Sigma Aldrich), 5 mM ATP, 0.25 mM 
NADH (β-Nicotinamide adenine dinucleotide) and 1.25 mM PEP[phosphor(enol)pyruvic acid] at 
37 ºC for 10 min, as described previously (30).  The reaction was started by addition of 2.5 mM 
MgCl2.  The optical density at 340 nm was monitored for 10 min using Shumadzu UV1601 
spectrophotometer and the UV probe 2. 20 Kinetics software.  The slope of the linear portion of 
each curve (between 200 s and 400 s) was used to calculate ATPase activity.  The activity of the 
control IOVs (without DrrAB) was subtracted from the activity of each test sample to obtain 
DrrAB-specific activity.  Relative activity was then calculated by dividing the activity of each 
sample by the activity of the wild type sample.   
2.7 Results 
Characterization of the DrrAB-mediated Dox efflux under in vivo and in vitro conditions – 
An in vivo assay for studying DrrAB-mediated Dox efflux was reported previously (58,61) and is 
shown in Fig. 1A.  In this study, we established conditions to study DrrAB-mediated Dox efflux 
under in vitro conditions using E. coli inside out membrane vesicles (IOVs) (Fig. 1B).  Both in 
vivo and in vitro assays utilize the fluorescent nature of Dox to measure efflux in E. coli 
LE392ΔuncIC cells (or IOVs).  This strain of E. coli contains a deletion in the unc genes; as a 
result it is unable to carry out synthesis of ATP using proton gradients or establish a proton 
gradient by hydrolysis of ATP (96).  Therefore, it is possible to establish conditions where only 
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the proton motive force (pmf) or ATP is available as a source of energy (described below).  Dox 
is fluorescent in solution, however its accumulation inside the cells results in quenching of its 
fluorescence and its efflux results in an increase in fluorescence intensity (97). 
In vivo Dox efflux – The basic strategy for studying efflux under in vivo conditions consists of 
loading of the de-energized cells with Dox (58), followed by addition of an energy source, which 
is expected to result in efflux of Dox and an increase in its fluorescence (Fig. 1A).  Under the 
conditions used in our experimental system, use of succinate as energy will generate only proton 
motive force while glucose will generate both pmf and ATP, therefore allowing us to 
discriminate between the energy sources used by the DrrAB system.  The data in Fig. 1A 
compare the rate of Dox efflux in DrrAB-containing cells in the presence of glucose or succinate.  
E. coli LE392ΔuncIC cells (containing empty vector) were used as negative control in these 
experiments.  Two conclusions can be made from the data shown in Fig. 1A.  First, the rate of 
Dox efflux by the DrrAB-containing cells in the presence of glucose is about 5-fold higher as 
compared to the rate in control cells (Fig. 1A.2, compare columns 1 and 4). A small increase in 
Dox efflux efficiency seen in control cells on addition of glucose is likely due to the action of 
one of the several MDR pumps known to be present in E. coli (87).  Secondly, in contrast to 
glucose, use of succinate as energy showed no increase in fluorescence intensity in DrrAB-
containing cells (Fig. 1A.1, curve 2; Fig. 1A.2, column 2), indicating that pmf does not support 
Dox efflux by the DrrAB proteins.  Confirmation of these results was obtained by addition of 
sodium fluoride, a specific inhibitor of ATP synthesis by substrate-level phosphorylation, to 
DrrAB-containing cells in the presence of glucose.  The data show a drastic reduction in Dox 
efflux by the DrrAB-containing cells (Fig. 1A.1, curve 3; Fig. 1A.2, column 3), resulting in the 
same background levels of efflux as seen with succinate (column 2).  These studies show that 
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doxorubicin efflux by the DrrAB pump is solely ATP-dependent, and pmf is not required for this 
process, thus highlighting similarities between DrrAB and other MDR proteins of the ABC 
superfamily (6,27,98). 
In vitro Dox efflux – To understand the kinetics of Dox transport, an in vitro Dox efflux assay 
was optimized using inside-out membrane vesicles, as described under Methods.  In this assay, 
the vesicles were mixed with Dox, and efflux was initiated by addition of ATP and Mg
2+
.  
Because of the inverted nature of the IOVs, DrrAB-mediated efflux results in accumulation of 
Dox inside the vesicles which is seen as quenching of its fluorescence (Fig. 1B.1).  The data in 
Fig. 1B.1 show that addition of ATP/Mg
2+ 
first results in a rapid non-specific decrease in Dox 
fluorescence due to interaction between Dox and ATP (97).  This quick phase is then followed 
by a slower rate of quenching, which corresponds to the DrrAB-dependent efflux in the vesicles.  
The initial rate of Dox efflux was therefore determined from the linear slope of the fluorescence 
spectra between 100 s and 200 s.  As seen in Fig.1B.1 and 1B.2, Dox transport activity in 
vesicles containing DrrAB was found to be almost 12-fold higher as compared to the control 
vesicles prepared from cells containing vector alone (Fig. 1B.2, compare columns 1 and 4).  
Absence of either Mg
2+
 (column 2) or ATP (column 3) resulted in the failure of these vesicles to 
transport Dox.  Use of NADH as an energy source also did not support Dox efflux (column 6), 
once again confirming that proton motive force is not used by the DrrAB proteins as a source of 
energy.  Surprisingly, when GTP was used as an energy source instead of ATP, even higher 
transport activity was observed (column 5).  Dox-dependent ATP and GTP binding to DrrA was 
shown previously (48).  Together these data indicate that either ATP or GTP (and Mg
2+
) can 
serve as a source of energy for the Dox transport function of DrrAB. 
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Kinetic Analysis of Dox efflux in vitro –To understand the kinetics of Dox efflux by the DrrAB 
system, efflux was analyzed (as shown in Fig. 1B.1) at a wide range of Dox concentrations.  The 
initial rate (slope between 100 s-200 s) of each efflux curve was determined.  Efficiency of Dox 
efflux was then calculated, as described under Methods and Figure Legends.  The data were 
fitted to a hyperbola using the Michaelis-Menten equation (with an R
2
 of 0.89), yielding an 
apparent Km of 0.38 µM and Vmax of 1003 (arbitrary units, a.u.) (Fig. 1C).  These data showed a 
linear increase in the rate of Dox transport at concentrations ranging between 0.1 µM and 1 µM, 
which became saturated after 3µM.  The Dox transport data could also be fitted equally well by 
the Hill equation; the implication of this finding is discussed later. 
Inhibition of Dox transport activity by sodium o-vanadate – Vanadate (Vi) is a known 
inhibitor of the ATPase activity of ABC proteins (99-102).  Since it functions as an analog of Pi, 
the ADP·Vi·Mg
2+ 
complex is trapped in the ATP binding pocket after a single catalytic turnover, 
thus blocking further hydrolysis of ATP as well as drug transport.  To determine if the DrrAB 
system is inhibited by vanadate, Dox transport was measured in IOVs in the absence or presence 
of increasing amounts of vanadate (5 µM to 100 µM).  The data in Fig. 1D show that vanadate is 
a potent inhibitor of the Dox transport of DrrAB, with an IC50 = 11 µM.  A complete inhibition 
of the Dox transport activity was seen at 100 µM vanadate.  These data are consistent with the 
previously reported studies on the inhibitory effect of vanadate on Pgp and MsbA (101,103).  
Point mutations in the nucleotide binding domain of DrrA compromise Dox transport 
activity – The N-terminal nucleotide binding domain of DrrA contains a 200 amino acids long 
ABC cassette consisting of all the conserved motifs (Walker A, Walker B, Signature motif/C-
loop, Q-loop, and the Switch motif/H-loop) involved in ATP binding and hydrolysis (Fig. 2A.1).  
We previously reported that mutations in the conserved residues of DrrA confer Dox sensitivity 
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(104).  Mutations in Walker A, as expected, also compromised ATP binding (104).  Here we 
evaluated the effect of several mutations on DrrAB-mediated Dox efflux in IOVs.  The data in 
Fig. 2B show that, as expected, single point mutations in Walker A (such as G44A, G44S or 
K47R), signature (S141R), or the Walker B (E165Q) motif of DrrA result in a drastic effect on 
Dox transport activity.  Since the sequence of the Switch motif of DrrA is different from most 
other ABC proteins (Fig. 2A), this region was analyzed in greater detail, as described below.  
Most ABC proteins normally contain a highly conserved histidine residue in their Switch motif, 
followed by an arginine, histidine, or a lysine (Fig. 2A.1).  The conserved histidine of the Switch 
motif and a conserved glutamate immediately following the Walker B motif (both are shown as 
highlighted areas in Fig. 2) are together believed to be critical for formation of the active sites in 
ABC proteins.  Zaitseva et al recently proposed that these two residues together form a catalytic 
dyad which functions in substrate-assisted catalysis (105).  However, despite the high 
conservation of these two residues in ABC proteins, deviations in the sequence of these motifs 
are sometimes seen.  Most commonly, a glutamine replaces the histidine in the Switch motif and 
an aspartate replaces the glutamate in the Walker B region.  When present (for example in TAP1 
and LmrC), these deviations are seen to result in asymmetrical ATP binding pockets with one 
site being catalytically non-functional (106,107).  Interestingly, however, despite the presence of 
the non-canonical glutamine residue (Q197 followed by Y198, resulting in QY sequence) in the 
Switch motif of DrrA (as well as its close prokaryotic homologs, Fig. 2A.2), it is able to form a 
functional drug transporter with DrrB, as seen in Fig. 1.  Note that the close eukaryotic homologs 
of DrrA most often contain an HH sequence in the Switch region (Fig. 2A.3), and both 
prokaryotic and eukaryotic groups contain the conserved glutamate in the Walker B region 
(specifically E165 in DrrA) (Figs. 2A.2 and 2A.3)   
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Since histidine is conserved in the Switch of most ABC proteins, we wondered if the 
DrrAB transporter will become more efficient if Q197 is substituted with a histidine or if the QY 
sequence is changed to the commonly occurring sequence HR or HH.  Surprisingly, we found 
that the Q197H mutation in DrrA produces a drastic effect on Dox efflux, however mutation of 
Y198 to Y198R retains about 35% Dox efflux function (Fig. 2C).  Interestingly, a double 
mutation HR (Q197H/Y198R) also resulted in Dox transport activity of about 38% indicating 
that the second mutation partially masked the harmful effect of the Q197H single mutation (Fig. 
2C).  By contrast, the double mutation HH (Q197H/Y198H) exhibited extremely low Dox efflux 
(Fig. 2C).  To understand the role of Q197 and Y198 in catalysis, the effect of the above-
mentioned mutations on the ATPase activity of the DrrAB complex was determined.  We found 
that while Q197H produces a drastic effect on ATPase activity, both HR and HH double 
mutations show significant ATPase activity (43% and 61%, respectively) (Figs. 2D and 2E), 
indicating that the second mutation in each case partially compensates for the negative effect of 
the Q197H mutation on catalysis.  Overall the findings in Fig. 2 indicate that residues Q197 and 
Y198 in the Switch motif of DrrA function together and that the QY sequence works much better 
than the HH or HR sequence for the overall Dox efflux function of the DrrAB complex.  
Interestingly, the HH double mutant still exhibits 60% ATP hydrolysis activity, which suggests 
that either the QY or the HH sequence could participate in the formation of functional catalytic 
sites in DrrA.  However, the HH allele seems to be defective in specific communication between 
DrrA and DrrB resulting in significantly reduced Dox efflux (less than 5%).  Therefore the 
context in which the Switch motif functions in different ABC proteins may determine the nature 
of this motif.  The conserved glutamate E165 present near the Walker B region served as a 
control in these experiments.  Analysis of the E165Q mutation showed a drastic effect on both 
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hydrolysis of ATP and Dox efflux (Figs. 2B-D), which is consistent with the critical role of this 
residue previously reported in literature (108).  How a glutamine residue participates in the 
formation of functional ATP binding pockets in DrrA is still an open question.  However, we can 
draw from the analogous situations present in other ATP/GTP-binding proteins (including RecA 
and H-ras p21) which contain a catalytic glutamine residue (Q194 in RecA and Q61 in H-ras 
p21) in their switch II domain in the position corresponding to Q197 in DrrA (1,109,110).  The 
3-d structures of RecA and H-ras indicate that these glutamines show similar interactions with 
the catalytic glutamate and γ phosphate of ATP to those seen with histidine in the ABC proteins, 
therefore suggesting that the glutamine functions in a manner similar to histidine in producing 
the overall conformation of the active site.  This is consistent with our observation that either QY 
or HH sequence can indeed participate in formation of the catalytic sites in DrrA although the 
HH sequence is deficient in energy transduction.  In summary, the analyses in Fig. 2 confirm that 
a functional nucleotide binding domain of DrrA is essential for Dox efflux by the DrrAB system.  
The analysis of the Switch mutations, in particular, also indicates that the in vitro efflux assay 
described here can provide a sensitive and a valuable approach for elucidating the role of critical 
residues in the catalytic and drug transport function of the DrrAB complex.   
DrrAB-mediated Dox efflux is inhibited by multiple MDR substrates – To determine if the 
DrrAB transporter can recognize and bind other known MDR substrates, inhibition of Dox efflux 
by different drugs was investigated in IOVs.  These assays were carried out at a wide range of 
the inhibitor concentrations while maintaining a constant concentration of Dox, as described 
under Methods (determination of IC50 values).  The data in Fig. 3 show that many known MDR 
drugs, including H 33342 (H 33342) (Fig. 3A), verapamil (Fig. 3B), and rifampicin (Fig. 3C), 
inhibit DrrAB-mediated Dox efflux with high efficiency.  The data in Fig 3, panel D, summarize 
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the inhibitory effects of many different MDR substrates and indicate that the IC50 values vary 
dramatically for different substrates. For example, H 33342, vinblastine, verapamil and 
rifampicin show relatively low IC50 values, while much higher concentrations of EtBr, quinidine, 
and colchicine were required for the same level of inhibition.  These data suggest that the DrrAB 
system has multiple substrates, which bind with varying affinities. However, whether these drugs 
bind to the same site, or if there are multiple drug binding sites, can’t be ascertained from these 
data.  To understand the nature of drug binding, kinetics of DrrAB-mediated Dox efflux was 
studied at multiple Dox concentrations in the presence of several concentrations of each 
inhibitory drug, which is described below.  
Kinetics of Dox Inhibition by MDR drugs – The data in Fig. 1C showed that the rate of Dox 
efflux by DrrAB-containing IOVs increases linearly between 0.1 µM and 1 µM Dox 
concentration, therefore four evenly distributed concentrations of Dox within this range (0.25, 
0.50, 0.75, and 1.0 µM) were used in the kinetics analysis.  At each concentration of Dox, efflux 
was measured in the presence of our different concentrations of H 33342, verapamil, or 
rifampicin.  These drugs were chosen based on their low IC50 values seen in inhibition studies 
(Fig.3D).  (Since Dox and ethidium together were incompatible in the fluorescence-based assays 
due to their overlapping excitation/emission spectra, this combination could not be used in this 
study).  The initial slope (100-200 seconds) for each Dox efflux curve was determined.  The 
slope of the Dox efflux curve at 1.0 µM Dox and 0 concentration of the inhibitor was designated 
as 1, which was then used to calculate the relative slope of each curve obtained in the presence of 
the inhibitor, as described under Methods. The relative slopes were plotted by the Lineweaver-
Burk plots using the Sigma Plot kinetics software (Fig. 4).  The data in Fig. 4A indicate that the 
inhibition of Dox efflux by H 33342 is characteristic of competitive inhibition; the Km of DrrAB-
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mediated Dox transport increased at increasing concentration of H 33342, whereas the Vmax 
remained unchanged.  These data suggest that Dox and H33342 may bind to the same site in 
DrrAB.  The apparent inhibition constant (Ki for H33342) was found to be 0.64 µM, which 
corresponds well to the IC50 value of H 33342 (Fig 3, panel D).  When studying the inhibition of 
Dox transport by rifampicin, a similar pattern was observed, which indicated a competitive 
inhibition between Dox and rifampicin (Fig. 4C).  However, the kinetics of inhibition of Dox 
transport by verapamil showed a different pattern (Fig. 4B).  The Vmax decreased at increasing 
concentration of verapamil, while Km remained unaltered, indicating a non-competitive inhibition 
between Dox and verapmail.  These data suggest that verapmail may bind to both the unliganded 
DrrAB and the binary DrrAB-Dox complex.  The Ki value for verapamil inhibition was found to 
be 9.4 µM, which also matches well to the IC50 of verapamil (Fig. 3, panel D).  The observed 
competitive and non-competitive inhibitions of DrrAB-mediated Dox transport in IOVs imply 
that DrrAB must contain at least two drug binding sites.  
The DrrAB system is a multidrug transporter – To determine whether the DrrAB system can 
actually transport other drugs in addition to Dox, two substrates (H 33342 and EtBr) commonly 
used to establish the MDR phenotype (5,27), were tested in IOVs, as described under Methods.  
In addition, five other fluorescent dyes or drugs (including Hoechst 34580, Hoechst 33258, 
quinine, TMRM, and Rhodmine 123) were also tested.  Of these substrates, H 33342 and EtBr 
were successfully transported by the DrrAB system, as described below.  
Hoechst is a cell-permeable dye, which is fluorescent only when bound to the cell 
membrane and loses its fluorescence in aqueous environment.  Thus a decrease in fluorescence is 
expected when Hoechst is transported by the DrrAB system from the membrane to the inner 
aqueous environment in the IOVs. Ethidium bromide, on the other hand, becomes fluorescent 
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when bound to DNA inside the cells.  Therefore, DrrAB-mediated efflux of EtBr was studied in 
preloaded cells, as described under Methods.  EtBr efflux under this condition is expected to 
result in quenching of fluorescence.  The data in Fig. 5 show that both H 33342 (Fig 5A.1) and 
EtBr (Fig 5B.1) are transported efficiently by the DrrAB system.  In the case of H 33342, the rate 
of transport was seen to decrease after an initial linear phase of transport.  This is likely due to 
depletion of H 33342 in the membrane and due to passive rebinding of H 33342 to the membrane 
from the aqueous phase, as shown earlier in the case of Pgp (27).  To determine the kinetic 
parameters for the transport of H 33342 and EtBr, efflux of each substrate was analyzed at a 
wide range of concentrations.  The initial rate of H 33342 transport in DrrAB-containing IOVs 
was measured between 0.1 µM and 2.5 µM (Fig 5A.2).  The efficiency of H 33342 transport was 
calculated, as described earlier for Dox (Fig. 1C).  The data were plotted using the Michaelis-
Menten equation by the Sigma Plot kinetics software and could be fitted to a hyperbola with an 
R
2
 of 0.90, yielding an apparent Km of 0.78 µM and Vmax of 16000 (a.u.).  To study kinetics of 
EtBr transport, energy-depleted cells were loaded with different concentrations of EtBr (ranging 
from 1 µM to 100 µM) for 1 hour, and efflux was initiated by addition of 20 mM glucose (Fig 
5B.2).  The data fitted to the hyperbola (Michaelis-Menten equation) with an R
2
 of 0.97, yielding 
an apparent Km of 21µM and Vmax of 550 (a.u.).  The data in Fig 5 show that both H 33342 and 
EtBr are transported efficiently by the DrrAB system.  A comparison of the Km and Vmax values 
for transport of Dox, H 33342, and EtBr is shown in Fig 5, panel C.  Five other fluorescent 
substrates (Hoechst 34580, Hoechst 33258, quinine, tetramethylrhodamine(TMRM), and 
Rhodmine 123) tested in this study were not found to be exported by the DrrAB system (data not 
shown).  In general, the transport data agreed with the inhibition data shown in Fig. 3, panel D.  
Interestingly, of the three Hoechst dyes tested, only H 33342 was transported.  Recent studies 
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showed that a certain balance between the hydrophobic and hydrophilic forces in the structure of 
the target substrate is essential for optimum efflux by Pgp (111).  Since H 33342 is the most 
amphiphilic of the three dyes, this may explain why DrrAB is able to preferentially transport H 
33342 but not the other two dyes.  
2.8 Discussion 
Multidrug resistance is conferred by the action of specialized proteins in the cell 
membrane that have the ability to carry out energy-dependent efflux of structurally and 
functionally unrelated hydrophobic compounds.  This phenomenon defies the concept of single 
enzyme-single substrate (the lock and key model), which is applicable to most other enzymes.  
Since the discovery of multidrug resistance in human cancer cells and bacteria (112-114), two 
important questions have remained at the forefront of this field: 1) what is the basis of poly-
specific drug recognition and transport by MDR proteins? 2) How and why does MDR evolve?  
Extensive biochemical analysis of Pgp (87,89,90) as well as the availability of three-dimensional 
structures of the drug-bound forms of Pgp, AcrB, BmrR and QacR (42,91,115,116) has 
contributed significantly to understanding the molecular basis of poly-specific drug binding.  
These studies indicate that the MDR proteins contain an extensive (and flexible) drug binding 
pocket which can accommodate multiple drugs simultaneously via interactions with specific 
(sometimes overlapping) aromatic and polar residues present in different parts of the pocket.  
The 3-D structure of Pgp, in particular, also provides support for the hydrophobic vacuum 
cleaner model, which was proposed early on by Gottesman and colleagues (4,17) to explain the 
mechanism of multidrug transport.  According to this model, Pgp substrates (which are primarily 
cationic, lipid soluble, planar molecules) partition spontaneously into the membrane and are 
picked up by Pgp directly from the membrane (instead of from the cytoplasm) and then removed 
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by its ability to flip drugs from the inner to the outer leaflet.  This model, which has now been 
extended to many other MDR proteins (21), makes a clear distinction between the classical 
solute transporters that remove molecules from an aqueous compartment and the MDR proteins 
that are proposed to function as flippases (117).  A clear relationship between the ability of drugs 
to partition into the membrane and their binding and transport by Pgp has since been documented 
(24,118,119).  Additional evidence in support of this model comes from 1) the ability of most 
MDR proteins studied to date to extrude the lipopilic dye H 33342 directly from the membrane 
(7,27,32,120), thus making it an ideal molecule to establish the MDR phenotype and 2) the 
ability of many MDR proteins to flip-flop lipids (121-124).  Together, these observations led to 
the idea that hydrophobic drugs and lipids may use a common pathway or flipping mechanism 
for extrusion. 
Despite significant progress in understanding the basis of poly-specific drug-binding, the 
origin of multidrug resistance still remains an enigma.  It is generally accepted that most of the 
antibiotic and drug resistance genes found in clinical settings have their origins in the 
environmental bacteria (87).  Indeed many antibiotic producing organisms contain dedicated 
export systems to protect themselves against their own antibiotics (125,126).  Understanding 
these systems could hold the key to unraveling the origin and evolution of multidrug specificity.  
It is generally assumed that the dedicated systems found in producer organisms belong to the 
category of single-drug transporters as opposed to multi-drug transporters (88), however their 
substrate specificity has never been investigated in any significant detail thus providing the 
impetus for this study. 
We show for the first time that the DrrAB system functions as a typical multidrug 
transporter that can carry out efflux of structurally unrelated substrates, including Dox, ethidium 
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bromide and H 33342.  Inhibition studies further demonstrate that the substrate range of the 
DrrAB system includes many additional substrates, such as verapamil, vinblastine, and rifamicin, 
among others.  Thus the substrate specificity of DrrAB overlaps with most other known MDR 
proteins, including Pgp (127-129).  We found, however, that unlike Pgp, neither quinine nor 
rhodamine 123 serve as substrates for export by the DrrAB system nor did they show inhibition 
of Dox transport.  Therefore, in spite of the broad substrate range of DrrAB, it appears that the 
range of substrates recognized by Pgp may still be larger (130), implying that the ability to bind 
some of these substrates may have evolved later in Pgp.  Interestingly, the IC50 values varied 
significantly among different drugs, indicating the different binding affinities of each substrate.  
The highest IC50 was observed for colchicine, which is consistent with the data previously 
reported for Pgp (118,131,132).  This may be related with low hydrophobicity of colchicines 
(133), therefore indicating that the ability to partition into the membrane may be an important 
factor for transport by both Pgp and DrrAB.   
Kinetic characterization of Dox, H 33342, and EtBr transport by the DrrAB system 
revealed single-site transport kinetics.  Further, the Km values of 0.38 µM and 0.78 µM for 
transport of Dox and H33342, respectively, reflect high affinity of these substrates for the DrrAB 
system and correspond well with the Km values seen earlier for Dox transport by Pgp (134) and 
Hoechst transport by MsbA and LmrA (5).  Interestingly, however, we found that the kinetic data 
for Dox as well as H 33342 could also be fitted by the Hill equation (shown in Fig. 5C) 
providing the nHill value of 1.7 for Dox (R
2
 = 0.93) and 2.0 for H 33342 (R
2
 = 0.95), which 
suggests co-operative interaction between two or more drug binding sites in DrrAB.  It is not 
clear from these data, however, whether both H 33342 and Dox bind to the same sites in the 
DrrAB system.  Since ethidium transport by DrrAB exhibited only single-site transport kinetics 
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(nHill=1.1; R
2
 = 0.98) (Fig. 5C), it possibly interacts with only one of the Dox/Hoechst binding 
sites, or it may bind to a completely different site in DrrAB.  The kinetic analyses shown in Fig. 
4 provide evidence for competitive inhibition of Dox transport by H 33342 and rifampicin and 
non-competitive inhibition by verapamil.  Therefore, we conclude that both H33342 and 
rifampicin bind to the same site(s) as Dox, whereas verapamil may bind to a different site in 
DrrAB.  Evidence for two or more non-identical drug binding sites has also been obtained 
previously with MsbA (5,122), LmrA (6) and Pgp (5,34,135).  In Pgp, the two sites were defined 
as the H and R sites based on their preferential binding to Hoechst and Rhodamine, respectively 
(136).  Together, these data point towards the presence of two or more drug binding sites in the 
DrrAB system.  Gleaning from the knowledge previously gained from studies with Pgp and 
AcrB, these different drug binding sites are likely part of the same binding pocket in DrrB.  
However, in the absence of a crystal structure of the DrrAB transporter, this conclusion is only 
tentative.   
Even though the present study does not provide an answer to the origin of poly-specific 
drug recognition, it does indeed show that a simple system like DrrAB (which may be closely 
related to the ancestral system) already contains the ability to recognize and transport multiple 
substrates.  This leads us to conjecture that the ability to transport multiple drugs is an inherent 
property of a certain class of proteins that followed a different evolutionary path than the 
classical transporters.  This work also opens new questions regarding the mechanism by which 
the DrrAB system extrudes multiple hydrophobic substrates.  The most important of these 
questions is whether this system relies on a hydrophobic vacuum cleaner-like mechanism and if 
it is capable of flippase action?  Doxorubicin is produced inside S. peucetius cells, therefore 
presumably the function of the DrrAB system is to remove it from the cytoplasmic compartment 
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to the outside.  Being amphipathic, however, Dox could conceivably partition into the cell 
membrane and then be picked up by the DrrB protein directly from the membrane, as suggested 
in an early model proposed for AcrB function (91).  This strategy for its removal could also 
provide protection to the cell from the toxic effects of free Dox inside the cell.  The ability to 
transport Hoechst no doubt indicates that the DrrB protein can indeed extract this fluorescent dye 
directly from the membrane by a mechanism similar to the one used by Pgp and other proteins 
(5,27,129).  Future studies will therefore focus on an in-depth analysis of the mechanism of drug 
extrusion by the DrrAB system.  
This and previous studies on MDR proteins raise many other intriguing questions; for 
example, is there evolutionary relatedness between MDR proteins and lipid flippases?  What is 
the real difference between the single-drug and multi-drug transporters?  What makes certain 
proteins specific for a substrate and some others multi-specific?  What is the contribution of high 
aromatic amino acid content of the TM helices of MDR proteins in conferring poly-specificity?  
Since the transmembrane helices of Pgp and other MDR proteins, such as the bacterial BMR, are 
highly enriched in aromatic amino acids (18% and 15.4% for Pgp and BMR, respectively) as 
compared to the single-drug transporter TetA (9.4%), Pawagi et al. proposed that a greater 
number of aromatic amino acids may correlate with a decrease in substrate specificity of a 
transporter by providing additional binding sites for drugs containing aromatic rings in their 
structure (137).  Moreover, it was shown that mutagenesis of a single residue Ser941 to Phe in 
TM11 of Pgp significantly altered its drug efflux profile (138).  The recent 3-D structure 
confirmed that the drug-binding pocket of Pgp is made up of mostly hydrophobic and aromatic 
residues (42).  Interestingly, we found that the aromatic amino acid content of predicted TM 
helices of DrrB (84) is also relatively high (15%) which is close to the aromatic content of Pgp 
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(18%) and BMR (15.4%).  Whether this plays a role in conferring multi-specificity in DrrB will 
be determined in future studies by mutagenesis of specific aromatic and other residues in DrrB. 
 
 
 
 
 
 
 
Table 3.1 Bacterial strains and plasmids 
 
  
Name Description Reference 
               Bacterial Strains or Plasmid 
LE392 ΔuncIC supE44 supF58 hsdR514 galK2 galT22 metB1 trpR55 
lacY1  Δ uncIC 
(96) 
pSU2718 Cloning vector, pACYC184 derivative, Cm
r
 (59) 
pDX101 drrAB in pSU2718, Cm
r
 (59) 
pDX102 drrA in pSU2718, Cm
r
 (59) 
pDX103 drrB in pSU2718, Cm
r
 (59) 
pDX101(G44A) drrAB in pSU2718 with mutation of Gly
44
 to Ala
44
 in 
the Walker A domain of drrA 
(104) 
pDX101(G44S) drrAB in pSU2718 with mutation of Gly
44
 to Ser
44
  in 
the Walker A domain of drrA 
(104) 
pDX101(K47R) drrAB in pSU2718 with mutation of Lys
47
 to Arg
47
  in 
the Walker A domain of drrA 
(104) 
pDX101(S141R) drrAB in pSU2718 with mutation of Ser
141
 to Arg
141
  
in the Signature domain of drrA 
(104) 
pDX101(E165Q) drrAB in pSU2718 with mutation of Glu
165
 to Gln
165
 
in the Walker B domain of drrA 
(104) 
pDX101(Q197H) drrAB in pSU2718 with mutation of  Gln
197
 to His
197
  
in the switch motif of drrA 
This study 
pDX101(Y198R) drrAB in pSU2718 with mutation of  Tyr
198
 to Arg
198
  
in the switch motif of drrA 
This study 
pDX101(Q197H/Y198R) drrAB in pSU2718 with mutation of  Gln
197
 Tyr
198 
to 
His
197
 Arg
198
 in the switch motif of drrA 
This study 
pDX101(Q197H/Y198H) drrAB in pSU2718 with mutation of  Gln
197
 Tyr
198 
to 
His
197
His
198
 in the switch motif of drrA 
This study 
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Figure 3.1 Characterization of the DrrAB-mediated Dox efflux under in vivo and in 
vitro conditions. 
These data were contributed by Wen Li and Madhu Sharma 
 
FIGURE 3.1 Characterization of the DrrAB-mediated Dox efflux under in vivo and in vitro 
conditions.  (A) In vivo analysis of DrrAB-mediated Dox efflux using E. coli cells. E. coli 
LE392ΔuncIC cells containing either vector or pDX101 (DrrAB) were loaded with 10 µM Dox, 
and the whole cell Dox efflux assay was performed, as described under Methods and in ref (61).  
Dox efflux was measured fluorometrically (exi, 480 nm; emi, 590 nm) on an Alphascan-2 
spectrofluorometer (Photon Technology International).  Energy was provided in the form of 20 
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mM glucose or 20 mM succinate at 100 seconds (marked with an arrow) and fluorescence was 
monitored for an additional 400 seconds.  10 mM sodium fluoride (NaF) was added to the 
samples, where indicated. A.1: Curve 1, pDx101(DrrAB)/glucose; Curve 2, pDx101 
(DrrAB)/succinate; Curve 3, pDx101 (DrrAB)/glucose/NaF; Curve 4, pSU2718 (vector)/glucose; 
Curve 5, pSU2718/succinate; Curve 6, pSU2718/glucose/NaF. A.2: Quantitative presentation 
of the Dox efflux data shown in Fig 1A.1.  The slope of the linear portion of each curve shown 
in Fig 1A.1 was calculated.  The slope of curve 1 was designated as 1.0.  Relative slope of each 
curve was then obtained by dividing the slope of the curve by the slope of curve 1.  The average 
data obtained from three independent experiments are shown in the histogram.  (B) In vitro 
analysis of DrrAB-mediated Dox efflux using inside-out membrane vesicles (IOVs). E. coli 
LE392ΔuncIC cells containing either vector or pDX101 (DrrAB) were grown to mid-log phase 
and induced with 0.25 mM IPTG at 37 °C for 3 hr.  The membrane fraction was prepared (49) 
and Dox efflux in DrrAB-containing IOVs was performed, as described under Methods. B.1: In 
vitro Dox efflux assay was carried out using 250 µg IOVs in the presence of 1 µM Dox, 0.1 
mg/ml creatine kinase and 5 mM creatine phosphate in 3 ml PBS buffer, pH 7.5, as described 
under Methods.  Vector, Dox efflux in IOVs prepared from cells containing empty vector; 
DrrAB, Dox efflux in IOVs prepared from cells containing pDX101 (DrrAB). B.2:  
Quantitative presentation of Dox efflux in DrrAB-containing IOVs under various 
conditions. In vitro Dox efflux assay was carried out in the presence or absence of 1 mM 
ATP,1mM GTP, 1 mM Mg or 5 mM NADH, as described under Methods.  The initial rate of 
Dox efflux was determined from the linear slope of the fluorescence spectra between 100 s and 
200 s.  The slope of the efflux curve obtained by incubation of the DrrAB-containing IOVs with 
ATP and Mg
2+
 (column 4) was designated as 1.0.  The relative slope for each curve was then 
65 
calculated by dividing the slope of the curve by the slope of sample 4.  The average data 
obtained from three independent experiments are shown in the histogram.  (C) Kinetic analysis 
of DrrAB-mediated Dox efflux in IOVs.  In vitro Dox efflux was analyzed using 250 µg IOVs 
in the presence of increasing concentrations of Dox (0.1 µM to 6.0 µM) and 1 mM ATP/Mg
2+
.  
The initial linear rate of Dox efflux was determined for each curve.  The data obtained from three 
independent experiments were fitted to the Michaelis-Menten equation and plotted by 
SigmaPlot-Kinetics software using the equation for Single Substrate Format.  (D) Inhibition of 
DrrAB-mediated Dox efflux by sodium o-vanadate. In vitro Dox efflux was measured using 
250 µg IOVs in the presence 1 µM Dox, 1 mM ATP and 1 mM Mg
2+
 and increasing 
concentrations of Vi (0 – 100 µM).  The initial slope of the efflux curve obtained with 0 µM Vi 
was designated as 1.0.  The relative slope of each curve was determined, as described underpanel 
A.2.  The average data obtained from three independent experiments are shown in the histogram.  
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Figure 3.2 Effect of point mutations in the nucleotide binding domain of DrrA on 
DrrAB-mediated Dox efflux in IOVs. 
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FIGURE 3.2  Effect of point mutations in the nucleotide binding domain of DrrA on 
DrrAB-mediated Dox efflux in IOVs.  (A) ClustalW alignment of the NBD of DrrA and its 
prokaryotic or eukaryotic homologs.  The conserved motifs present in the NBD are marked at 
the top.  A.1, alignment of the NBD of DrrA with ABC proteins (MalK, Sav1866, HlyB, TAP1, 
TAP2, LmrC, LmrD and LmrA) from diverse families.  A.2, alignment of the NBD of DrrA with 
close prokaryotic homologs (belonging to the DRA family/DRR subfamily (50) identified by 
NCBI BLAST. A.3, alignment of the NBD of DrrA with close eukaryotic homologs belonging to 
the DRA family/ABCA subfamily (50). (B) Effect of point mutations in Walker A, Walker B, 
or the Signature motif of DrrA on DrrAB-mediated Dox efflux in IOVs. E. coli 
LE392ΔuncIC cells containing either pSU2718 vector, pDX101 (drrAB in pSU2718), pDX102 
(drrA only, in pSU2718), pDX103 (drrB only, in pSU2718) or pDX101 containing mutations of 
Walker A (G44A, G44S, K47R), Signature motif (S141R), or the Walker B (E165Q) were 
induced with IPTG, and the IOVs were prepared, as described under Methods. The initial rate of 
Dox efflux was determined for each sample, and the relative slopes were calculated, as described 
for Fig. 1. The average data obtained from three independent experiments are shown in the 
histogram. (C) Effect of point mutations in the Switch motif of DrrA on DrrAB-mediated 
Dox efflux in IOVs.  E. coli LE392ΔuncIC cells containing either pSU2718 vector, pDX101 
(drrAB in pSU2718), or pDX101 with mutations of the Walker B region (E165Q) or the Switch 
motif (Q197H, Y198R, Q197H/Y198H, Q197H/Y198R) were induced with IPTG, and the IOVs 
were prepared, as described under Methods. The initial rate of Dox efflux was determined for 
each sample, and the relative slopes were calculated, as described for Fig. 1.  The data presented 
are averages of three independent experiments.  Error bars represent standard deviation.  (D) 
Effect of point mutations in the Switch motif of DrrA on DrrAB-mediated ATPase activity 
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in IOVs.  IOV samples from Fig. 2(C) were subjected to the NADH-coupled ATPase activity 
assay, as described under Methods.  The relative ATPase activity of each sample was obtained 
by dividing the activity of each sample by the activity of wild type.  The data presented are 
averages of two independent experiments.  Error bars represent standard deviation. (E) 
Summary of the ATPase activity and Dox efflux activity of wild type DrrAB and Switch 
motif mutants. 
 
 
 
Figure 3.3 Inhibition of DrrAB-mediated Dox efflux by known MDR substrates. 
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FIGURE 3.3 Inhibition of DrrAB-mediated Dox efflux by known MDR substrates.  Dox 
efflux was measured using 250 µg IOVs in the presence 1 µM Dox and increasing 
concentrations of the inhibitory substrate in 3ml PBS, pH 7.5.  The initial linear rate (100 s - 200 
s) of Dox efflux was determined after addition of 1mM ATP/Mg
2+
.  The slope of the efflux curve 
obtained at 0 concentration of inhibitor was designated as 1.0.  The relative slope of each curve 
was then determined.  The average slopes resulting from three independent repeats were plotted 
by Sigma Plot software using ‘scatter plot with error bars’, and IC50 values were determined. (A) 
Kinetic analysis of the inhibitory effect of Hoechst 33342 on Dox efflux activity.  The 
experimental conditions were the same as described above.  The assay was carried out in the 
presence of increasing concentrations of H 33342 ranging from 0 – 1.6 µM.  (B) Kinetic 
analysis of the inhibitory effect of verapamil.  The experimental conditions were the same as 
for Fig. 3(A), except that the concentration of verapamil ranged from 0 µM to 100 µM.  (C) 
Kinetic analysis of the inhibitory effect of Rifampicin.  The experimental conditions were the 
same as for Fig. 3(A), except that the concentration of rifampicin ranged from 0 µM to 75 µM.   
(D) A table showing summary of the IC50 values.  Kinetic analysis of the inhibitory effect of 
various drugs on DrrAB-mediated in vitro Dox efflux was determined, as described above for 
panels 3A-C.   The IC50 values were calculated as described under Methods. 
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Figure 3.4 Kinetic characterization of the inhibition of DrrAB-mediated Dox efflux 
by Hoechst 33342, verapamil or rifampicin 
 
FIGURE 3.4 Kinetic characterization of the inhibition of DrrAB-mediated Dox efflux by 
Hoechst 33342, verapamil or rifampicin.  The kinetics of DrrAB-mediated Dox efflux was 
determined in the presence of fixed concentrations of inhibitor, as shown in panels 4A-C.  (A) 
Competitive inhibition by H 33342.  DrrAB-mediated Dox efflux was studied at four different 
concentrations of Dox (0.25, 0.5, 0.75 and 1.0 µM) in the presence of a fixed concentration of 
H33342.  In total, four different concentrations of H 33342 (0, 0.2, 0.6, 0.8 µM) were studied.  
The rate of Dox transport obtained with 1 µM Dox and 0 µM H 33342 was designated as 1.0.  
The relative rates were then calculated for each efflux curve, and the data were plotted by 
Lineweaver-Burk plot using Sigma Plot- Kinetics software in Single Substrate – Single Inhibitor 
Kinetics Format.  The error bars represent three separate experiments.  The type of inhibition 
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was determined based on the rank of both AICc and R
2
. (B) Non-competitive inhibition by 
verapamil.  The experiment was performed as described under panel (A).  Four different 
concentrations of verapamil (0, 3.5,7, 14 µM) were used. (C) Competitive inhibition by 
rifampicin.  The experiment was performed as described under panel (A). Four different 
concentrations of rifampicin (0, 5, 10, 20 µM) were used.  (D) Summary of the kinetics 
constants obtained for inhibition of Dox efflux byH 33342, verapamil and rifampicin.   
 
 
Figure 3.5 The DrrAB system forms a multidrug transporter. (A.1) DrrAB-mediated 
Hoechst 33342 efflux in IOVs. 
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FIGURE 3.5  The DrrAB system forms a multidrug transporter. (A.1) DrrAB-mediated 
Hoechst 33342 efflux in IOVs.  The E. coli inside-out membrane vesicles were prepared, as 
described under Methods.  250 µg IOVs were mixed with 0.5 µMH 33342, 0.1 mg/ml creatine 
kinase and 5 mM creatine phosphate in 3ml PBS buffer, pH 7.4.  The fluorescence spectra were 
recorded on an Alphascan-2-spectrofluorometer with excitation of 355 nm and emission of 457 
nm.  After 100 s, the detection was paused, and 1mM Mg
2+
 and 1mM ATP, pH 7.5 were added 
into the reaction.  The detection was continued for additional 250 s.  Vector, IOVs prepared from 
cells containing empty vector; DrrAB, IOVs prepared from cells expressing DrrAB.  (A.2) 
Kinetic analysis of DrrAB-mediated H 33342 efflux in IOVs.  The experimental conditions 
were the same as described under A.1 above.  However, H 33342 efflux was analyzed at 
concentrations ranging between 0.1 µM to 2.5 µM. The initial (between 100 s-200 s) linear rate 
of H 33342 efflux was determined.  The data obtained from three independent experiments were 
fitted by the Michaelis-Menten equation using Sigma Plot – Kinetics software in Single 
Substrate Kinetics Format. (B.1) DrrAB-mediated ethidium bromide efflux in E. coli cells.  E. 
coli cells containing empty vector or DrrAB were loaded with 25 µM EtBr for 1 hr at 37 °C.  
Energy was provided in the form of 20 mM glucose, and EtBr efflux was measured, as described 
under Methods.  (B.2) Kinetic analysis of DrrAB-mediated EtBr Efflux in E. coli cells.  The 
experimental conditions were the same as described under B.1 above.  However, EtBr efflux was 
analyzed at concentrations ranging between 1 µM to 100 µM.  The steady-state linear rate of 
EtBr efflux was determined.  The data obtained from three independent experiments were fitted 
by the Michaelis-Menten equation using Sigma Plot – Kinetics software in Single Substrate 
Kinetics Format. (C) Summary of the kinetic parameters obtained by using Michaelis-
Menten or Hill equation for DrrAB-mediated Dox, H33342, and EtBr efflux.  
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4 GENERAL DISCUSSION 
The fast development of therapeutic agents has been compromised by the increasing 
problems of multidrug resistance both in infectious microorganisms as well as in cancer cells.  
Streptomyces peucetius, a soil microorganism that produces anti-cancer drugs Dox and Dnr, is 
self-resistant to these drugs due to the expression of the DrrAB drug efflux system on the 
membrane.  Because of the limited knowledge of the mechanism as well as the evolution of 
multidrug resistance, the prototype DrrAB system found in the producer organism can serve as 
an excellent model to understand various aspects of the phenomenon of MDR.   
In our current studies, we have demonstrated that DrrAB is a multidrug transporter.  It 
can efficiently transport Dox, Hoechst 33342 and ethidium bromide in whole cells as well as 
membrane vesicles.  Dox transport activity could be inhibited by verapamil, rifampicin, 
vinblastine and colchicine, suggesting that these drugs are also substrates of DrrAB.  DrrAB 
belongs to the ABC family of transporters and shares high similarities in sequence, structure and 
function with P-gp.  Our studies showed that DrrAB and P-gp share some of the substrates, 
although Pgp can transport a much larger range of structurally unrelated compounds.  Kinetics 
studies of drug efflux by DrrAB indicated competitive inhibition of Dox transport by Hoechst 
33342 and rifampicin but non-competitive inhibition by verapamil.  These studies raise 
intriguing questions about whether DrrAB contains more than one drug binding site, how these 
drugs interact with DrrB, and how does the conformation of DrrA and DrrB change during the 
drug transport process?  Further studies such as identification of the drug binding sites, analysis 
of specific drug transport mechanism in purified and reconstituted proteoliposome, and the cross-
talk between NBDs and TMDs during ATP binding, hydrolysis and drug efflux are required.  
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The drug binding sites of P-gp have been under investigation for several decades.  In 
early 1994, Pawagi and Deber showed that the TMHs of P-gp are highly enriched in aromatic 
amino acids (18%) as compared to the single-drug transporter TetA (9.4%) (137).  Later, Loo 
and Clark used biochemical approaches to identify the drug binding sites of P-gp.  Their work 
showed that the drug binding interfaces are located at TMHs 4, 6, 10, 11 and 12 (29,35,37-
39,139).   Substitution of a single serine to phenylalanine in TM11 of P-gp significantly altered 
its drug efflux profile, indicating the significant roles of residues in TMH11 in the recognition 
and transport of their specific substrates (138).  Not until recently, the crystal structure of P-gp 
with higher resolution was presented by Chang’s group (42).  In their description, P-gp with two 
bundles of six TMHs forms a large internal cavity open to both the inner leaflet and the 
cytoplasm.  The drug binding pocket is made up of mostly hydrophobic and aromatic residues; 
only 13 of the 73 residues in the internal cavity are polar or charged.  The upper half of the 
pocket contains mostly hydrophobic/aromatic residues while the lower half pocket mainly 
consists of charged/polar residues.  Interestingly, based on the topological structure and 
modeling analysis of DrrB (84), the aromatic amino acid content of predicted TMHs of DrrB 
(15%) is close to the aromatic content of P-gp (18%) and the bacterial MDR protein (15.4%) 
(137).  The hydrophobic and aromatic residues are mainly located in TMHs 1, 5, 6 and the N-
terminal loop of the single monomer of DrrB.  The N-terminal loop and TMH1 might be 
particularly important since they directly connect the TMDs of DrrB to the catalytic domain of 
DrrA (10).  To determine whether these domains are involved in drug binding, single point 
mutations can be introduced in the potential drug binding domains in DrrAB.  Mutations in any 
residues that are essential for drug binding will affect the transport of substrates (36,140,141).   
75 
Another major question of DrrAB drug transport is the cross-talk between DrrA and 
DrrB.  The role of the conserved EAA motif found in the first intracellular loop of the TMD in 
communication with the NBD has been studied in bacterial importers and exporters (142).  In our 
lab, we identified an EAA-like motif at the N-terminal cytoplasmic tail of DrrB (10).  Sequence 
alignment analysis showed that DrrB, LmrA, MDR1, CFTR, MsbA and BtuC share a conserved 
EAA-like motif.  Chemical cross-linking analysis indicated that DrrA cross-links with cysteines 
introduced in both the N-terminal and C-terminal ends of DrrB. Thus, this EAA-like motif may 
be involved in the interaction between DrrA and DrrB proteins.  Later in our laboratory, a 
CREEM motif (C-terminal Regulatory Glu (E)-rich Motif), located in the extreme C terminus of 
DrrA, was found to interact with the EAA-like motif in the N-terminal cytoplasmic tail of DrrB 
(10,61).  Taken together, both the EAA-like motif at the N terminus of DrrB and the CREEM 
motif at the C terminus of DrrA are significant for the interaction between DrrA and DrrB 
protein as well as the biogenesis of the DrrAB complex (61).  However, how energy is 
transduced between NBDs to TMDs and after the drug was transported still remains to be 
understood (143). 
In this work, I also studied the role of the FtsH protease in quality control and biogenesis 
of the DrrAB complex in the membrane.  FtsH was first identified by Ito and co-workers, who 
suggested that FtsH may be involved in protein assembly into and through the membrane and in 
determining the orientation of membrane proteins (73).  Chaperone function was also proposed 
for other ATP-dependent proteases, such as ClpAP/XP, YTA10/12 and Lon (144-147).  
However, no direct evidence for the role of FtsH or any other protease in the functional assembly 
of membrane proteins was obtained.  In our studies, we provide the first direct evidence that 
FtsH can perform both proteolytic and refolding functions in the assembly of the DrrAB 
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complex.  The most critical evidence for the refolding function of FtsH was obtained through the 
sequential expression studies. We show that FtsH expressed after nonfunctional DrrA and DrrB 
had accumulated in the membrane, was still able to restore the drug efflux function of the DrrAB 
complex.  Our studies also allow us to conclude that although the AAA domain of FtsH provides 
recognition and specificity for binding of the substrate, both ATP hydrolysis and the proteolytic 
functions of FtsH are used concurrently for the refolding of DrrAB and restoration of its efflux 
function.   
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